

Neurology®



The most widely read and highly cited peer-reviewed neurology journal
The Official Journal of the American Academy of Neurology

Neurology Publish Ahead of Print
DOI: 10.1212/WNL.0000000000011885

Global Impact of COVID-19 on Stroke Care and Intravenous Thrombolysis

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.

Authors: Raul G Nogueira, MD;^{1*} Muhammed M Qureshi, MPH;^{2,3} Mohamad Abdalkader, MD;² Sheila Ouriques Martins, MD PhD;⁴ Hiroshi Yamagami, MD PhD;⁵ Zhongming Qiu, MD PhD;⁶ Ossama Yassin Mansour, MD PhD;⁷ Anvitha Sathya;⁸ Anna Czlonkowska, MD PhD;⁹ Georgios Tsivgoulis, MD PhD;¹⁰ Diana Aguiar de Sousa, MD;¹¹ Jelle Demeestere, MD;¹² Robert Mikulik, MD PhD;¹³ Peter Vanacker, MD PhD;¹⁴ James E Siegler, MD;¹⁵ Janika Kõrv, MD PhD;¹⁶ Jose Biller, MD;¹⁷ Conrad W Liang, MD PhD;¹⁸ Navdeep S Sangha, MD;¹⁹ Alicia M Zha, MD;²⁰ Alexandra L Czap, MD;²⁰ Christine Anne Holmstedt, MD;²¹ Tanya N. Turan, MD;²¹ George Ntaios, MD;²² Konark Malhotra, MD;²³ Ashis Tayal, MD;²³ Aaron Loochtan, DO;²⁴ Annamarei Ranta, MD PhD;²⁵ Eva A. Mistry, MBBS;²⁶ Anne W Alexandrov, PhD;²⁷ David Y. Huang, MD PhD;²⁸ Shadi Yaghi, MD;²⁹ Eytan Raz, MD PhD;³⁰ Sunil A Sheth, MD;²⁰ Mahmoud H Mohammad, MD;¹ Michael Frankel, MD;¹ Eric Guemekane Bila Lamou, MD MSc;³¹ Hany M Aref, MD;³² Ahmed Elbassiouny, MD;³³ Farouk Hassan, MD;³⁴ Tarek Menecie, MD;³⁵ Wessam Mustafa, MD;³⁶ Hossam M Shokri, MD;³² Tamer Roushdy, MD;³³ Fred S Sarfo, MD;³⁷ Tolulope Oyetunde Alabi, MBBS, MWACP;³⁸ Babawale Arabambi, MBBS FWACP;³⁹ Ernest O Nwazor, MBBS FMCP;⁴⁰ Taofiki Ajao Sunmonu, MD;⁴¹ Kolawole Wahab, MBBS MPH MSc FMCP;³⁸ Joseph Yaria, MBBS, MSc;⁴² Haytham Hussein Mohammed, MD;⁴³ Philip B Adebayo, MBBS MSc FWACP FCP;⁴⁴ Anis D Riahi, MD;⁴⁵ Samia Ben Sassi, MD;⁴⁶ Lenon Gwaunza, MBChB, MSc;⁴⁷ Gift Wilson Ngwende, MBChB, FCP;⁴⁸ David Sahakyan, MD;⁴⁹ Aminur Rahman, MBBS FCPS FINR;⁵⁰ Zhibing Ai, MS;⁵¹ Fanghui Bai, MD;⁵² Zhenhui Duan, MD MS;⁵³ Yonggang Hao, MD;⁵⁴ Wenguo Huang, MS;⁵⁵ Guangwen Li, MD;⁵⁶ Wei Li, MD;⁵⁷ Ganzhe Liu, MD;⁵⁸ Jun Luo, MD MS;⁵⁹ Xianjin Shang, MD;⁶⁰ Yi Sui, MBBS PhD;⁶¹ Ling Tian, MD;⁶² Hongbin Wen, MD;⁶³ Bo Wu, MD;⁶⁴ Yuying Yan, MD;⁶⁵ Zhengzhou Yuan, MD;⁶⁶ Hao Zhang, MD PhD;⁶⁷ Jun Zhang, MD;⁶⁸ Wenlong Zhao, MD;⁶⁹ Wenjie Zi, MD;⁶ Thomas W. Leung, MD;⁷⁰ Chandril Chugh, MD;⁷¹ Vikram Huded, MD;⁷² Bindu Menon, MD FRCP;⁷³ Jeyaraj Durai Pandian, MD;⁷⁴ PN Sylaja, MD;⁷⁵ Fritz Sumantri Usman Sr, MD;⁷⁶ Mehdi Farhoudi, MD;⁷⁷ Elyar Sadeghi Hokmabadi, MD;⁷⁷ Anat Horev, MD;⁷⁸ Anna Reznik, MA;⁷⁹ Rotem Sivan Hoffmann, MD;⁷⁹ Nobuyuki Ohara, MD;⁸⁰ Nobuyuki Sakai, MD DMSc;⁸¹ Daisuke Watanabe, MD PhD;⁸² Ryoo Yamamoto, MD PhD;⁸³ Ryosuke Doijiri, MD;⁸⁴ Naoki Tokuda, MD PhD;⁸⁵ Takehiro Yamada, MD;⁸⁶ Tadashi Terasaki, MD;⁸⁷ Yukako Yazawa, MD;⁸⁸ Takeshi Uwatoko, MD;⁸⁹ Tomohisa Dembo, MD PhD;⁹⁰ Hisao Shimizu, MD;⁹¹ Yuri Sugiura, MD;⁹² Fumio Miyashita, MD;⁹³ Hiroki Fukuda, MD PhD;⁹⁴ Kosuke Miyake, MD;⁹⁵ Junsuke Shimbo, MD PhD;⁹⁶ Yusuke Sugimura, MD;⁹⁷ Yoshiki Yagita, MD PhD;⁹⁸ Yohei Takenobu, MD PhD;⁹⁹ Yuji Matsumaru, MD PhD;¹⁰⁰ Satoshi Yamada, MD PhD;¹⁰¹ Ryuhei Kono, MD;¹⁰² Takuya Kanamaru, MD PhD;¹⁰³ Hidekazu Yamazaki, MD;¹⁰⁴ Manabu Sakaguchi, MD PhD;¹⁰⁵ Kenichi Todo, MD PhD;¹⁰⁶ Nobuaki Yamamoto, MD PhD;¹⁰⁷ Kazutaka Sonoda, MD;¹⁰⁸ Tomoko Yoshida, MD;¹⁰⁹ Hiroyuki Hashimoto, MD PhD;¹¹⁰ Ichiro Nakahara, MD PhD;¹¹¹ Aida Kondybayeva, MD;¹¹² Kamila Faizullina, MD PhD;¹¹³ Saltanat Kamenova, MD;¹¹⁴ Murat Zhanuzakov, MD;¹¹⁵ Jang-Hyun Baek, MD;¹¹⁶ Yangha Hwang, MD PhD;¹¹⁷ Jin Soo Lee, MD;¹¹⁸ Si Baek Lee, MD;¹¹⁹ Jusun Moon, MD;¹²⁰ Hyungjong Park, MD;¹²¹ Jung Hwa Seo, MD;¹²² Kwon-Duk Seo, MD;¹²³ Sung Il Sohn, MD PhD;¹²¹ Chang Jun Young, MD;¹²⁴ Rechdi Ahdab, MD PhD;¹²⁵ Wan Asyraf Wan Zaidi, MMed;¹²⁶ Zariah Abdul Aziz, MMed;¹²⁷ Hamidon bin Basri, MD;¹²⁸ Law Wan Chung, MD;¹²⁹ Aznita Binti Ibrahim, MMed;¹³⁰ Khairul Azmi Ibrahim, MMed;¹²⁷ Irene Looi, MBBS;¹³¹ Wee Yong Tan, MD MRCP;¹³² Nafisah Wan Yahya, MMed;¹²⁶ Stanislav Groppa, MD PhD;¹³³ Pavel Leahu, MD;¹³³ Amal M. Al Hashmi, MD;¹³⁴ Yahia Zakaria Imam, MBBS MD MRCP;¹³⁵ Naveed Akhtar, MD;¹³⁵ Maria Carissa Pineda-Franks, MD;¹³⁶ Christian Oliver Co, MD;¹³⁶ Dmitriy Kandyba, MD;¹³⁷ Adel Alhazzani, MD;¹³⁸ Hosam Al-

Jehani, MBBS MSc;¹³⁹ Carol Huilian Tham, MBBS MMed MRCP;¹⁴⁰ Marlie Jane Mamauag, MD;¹⁴¹ Narayanaswamy Venketasubramanian, FRCP;¹⁴² Chih-Hao Chen, MD PhD;¹⁴³ Sung-Chun Tang, MD PhD;¹⁴³ Anchalee Churojana, MD;¹⁴⁴ Esref Akil, MD;¹⁴⁵ Ozlem Aykaç, MD;¹⁴⁶ Atilla Ozcan Ozdemir, MD;¹⁴⁶ Semih Giray, MD;¹⁴⁷ Syed Irteza Hussain, MD;¹⁴⁸ Seby John, MD;¹⁴⁸ Huynh Le Vu, MD;¹⁴⁹ Anh Duc Tran, MD;¹⁴⁹ Huy Hoang Nguyen, MD;¹⁵⁰ Thong Nhu Pham, MD;¹⁵⁰ Thang Huy Nguyen, MD;¹⁵¹ Trung Quoc Nguyen, MD;¹⁵¹ Thomas Gattringer, MD PhD;¹⁵² Christian Enzinger, MD;¹⁵² Monika Killer-Oberpfalzer, MD PhD;¹⁵³ Flavio Bellante, MD;¹⁵⁴ Sofie De Blauwe, MD;¹⁵⁵ Geert Vanhooren, MD;¹⁵⁵ Sylvie De Raedt, MD PhD;¹⁵⁶ Anne Dusart, MD;¹⁵⁷ Robin Lemmens, MD PhD;¹⁵⁷ Noemie Ligot, MD;¹⁵⁸ Matthieu Pierre Rutgers, MD;¹⁵⁹ Laetitia Yperzeele, MD PhD;¹⁶⁰ Filip Alexiev, MD PhD;¹⁶¹ Teodora Sakelarova, MD;¹⁶¹ Marina Roje Bedeković, MD;¹⁶² Hrvoje Budincevic, MD PhD;¹⁶³ Igor Cindrić, MD;¹⁶⁴ Zlatko Hucika, MD;¹⁶⁵ David Ozretic, MD;¹⁶⁶ Majda Seferovic Saric, MD PhD;¹⁶⁵ Frantiek Pfeifer, MD;¹⁶⁶ Igor Karpowic, MD;¹⁶⁷ David Cernik, MD;¹⁶⁸ Martin Sramek, MD;¹⁶⁹ Miroslav Skoda, MD;¹⁷⁰ Helena Hlavacova, MD;¹⁷¹ Lukas Klecka, MD;¹⁷² Martin Koutny, MD;¹⁷³ Daniel Vaclavik, MD;¹⁷⁴ Ondrej Skoda, MD;¹⁷⁵ Jan Fiksa, MD;¹⁷⁶ Katerina Hanelova, MD;¹⁷⁷ Miroslava Nevsimalova, MD;¹⁷⁸ Robert Rezek, MD;¹⁷⁹ Petr Prochazka, MD;¹⁸⁰ Gabriela Krejstova, MD;¹⁸¹ Jiri Neumann, MD;¹⁸² Marta Vachova, MD;¹⁸³ Henryk Brzezanski, MD;¹⁸⁴ David Hlinovsky, MD;¹⁸⁵ Dusan Tenora, MD;¹⁸⁶ Rene Jura, MD;¹⁸⁷ Lubomír Jurák, MD;¹⁸⁸ Jan Novak, MD;¹⁸⁹ Ales Novak, MD;¹⁹⁰ Zdenek Topinka, MD;¹⁹¹ Petr Fibrich, MD;¹⁹² Helena Sobolova, MD;¹⁹³ Ondrej Volny, MD PhD;¹⁹⁴ Hanne Krarup Christensen, MD PhD;¹⁹⁵ Nicolas Drenck, Bsc;¹⁹⁵ Helle Klingenberg Iversen, MD DMSci;¹⁹⁶ Claus Z. Simonsen, MD PhD;¹⁹⁷ Thomas Clement Truelsen, MD PhD;¹⁹⁶ Troels Wienecke, MD PhD;¹⁹⁸ Riina Vibo, MD PhD;¹⁹⁶ Katrin Gross-Paju, MD PhD;¹⁹⁹ Toomas Toomsoo, MD PhD;²⁰⁰ Katrin Antsov, MD;²⁰¹ Francois Caparros, MD MSc;²⁰² Charlotte Cordonnier, MD PhD;²⁰² Maria Dan, MD;²⁰³ Jean-Marc Faucheux, MD;²⁰⁴ Laura Mechtouff, MD;²⁰⁵ Omer Eker, MD PhD;²⁰⁶ Emilie Lesaine, MD;²⁰⁷ Basile Ondze, MD;²⁰⁸ Roxane Peres, MD;²⁰⁹ Fernando Pico, MD PhD;²¹⁰ Michel Piotin, MD PhD;²¹¹ Raoul Pop, MD PhD;²¹² Francois Rouanet, MD;²⁰⁷ Tatuli Gubeladze, MD PhD;²¹³ Mirza Khinikadze, MD PhD;²¹⁴ Nino Lobjanidze, MD;²¹⁵ Alexander Tsikaridze, MD PhD;²¹⁶ Simon Nagel, MD;²¹⁷ Peter Arthur Ringleb, MD;²¹⁷ Michael Rosenkranz, MD;²¹⁸ Holger Schmidt, MBBS;²¹⁹ Annahita Sedghi, MD;²²⁰ Timo Siepmann, MD;²²⁰ Kristina Szabo, MD;²²¹ Götz Thomalla, MD;²²² Lina Palaiodimou, MD;¹⁰ Dimitrios Sagris, MD;²²³ Odysseas Kargiotis, MD;²²⁴ Peter Klivenyi, MD PhD;²²⁵ Laszlo Szapary, MD PhD;²²⁶ Gabor Tarkanyi, MD;²²⁶ Alessandro Adami, MD;²²⁷ Fabio Bandini, MD;²²⁸ Paolo Calabresi, MD;²²⁹ Giovanni Frisullo, MD PhD;²²⁹ Leonardo Renieri, MD;²³⁰ Davide Sangalli, MD;²³¹ Anne V Pirson, MD;²³² Maarten Uyttenboogaart, MD PhD;²³³ Ido van den Wijngaard, MD PhD;²³⁴ Espen Saxhaug Kristoffersen, MD PhD;²³⁵ Waldemar Broła, MD PhD;²³⁶ Małgorzata Fudala, MD PhD;²³⁷ Ewa Horoch-Lyszczarek, MD;²³⁸ Michal Karlinski, MD PhD;²³⁹ Radoslaw Kazmierski, MD PhD;²⁴⁰ Pawel Kram, MD;²⁴⁰ Marcin Rogoziewicz, MD PhD;²⁴¹ Rafal Kaczorowski, MD;²⁴² Piotr Luchowski, MD;²⁴³ Halina Sienkiewicz-Jarosz, MD PhD;²⁴⁴ Piotr Sobolewski, MD PhD;²⁴⁵ Waldemar Fryze, MD PhD;²⁴⁶ Anna Wisniewska, MD;²⁴⁶ Malgorzata Wiszniewska, MD PhD;²⁴⁷ Patricia Ferreira, MD;²⁴⁸ Paulo Ferreira, MD;²⁴⁹ Luisa Fonseca, MD;²⁵⁰ João Pedro Marto, MD;²⁵¹ Teresa Pinho e Melo, MD;²⁵² Ana Paiva Nunes, MD;²⁵³ Miguel Rodrigues, MD MSc;²⁵⁴ Vítor Tedim Cruz, MD PhD;²⁴⁹ Cristian Falup-Pecurariu, MD PhD;²⁵⁵ Georgi Krastev, MD PhD;²⁵⁶ Miroslav Mako, MD;²⁵⁶ María Alonso de Leciñana, MD PhD;²⁵⁷ Juan F Arenillas, MD;²⁵⁸ Oscar Ayo-Martin, MD PhD;²⁵⁹ Antonio Cruz Culebras, MD;²⁶⁰ Exuperio Diez Tejedor, MD PhD;²⁵⁷ Joan Montaner, MD PhD;²⁶¹ Soledad Pérez-Sánchez, MD PhD;²⁶¹ Miguel Angel Tola Arribas, MA

MD PhD;²⁶² Alejandro Rodriguez Vasquez, MD;²⁶³ Michael Mazya, MD PhD;²⁶⁴ Gianmarco Bernava, MD;²⁶⁵ Alex Brehm, MD;²⁶⁶ Paolo Machi, MD PhD;²⁶⁵ Urs Fischer, MD MSc;²⁶⁷ Jan Gralla, MD;²⁶⁸ Patrik L. Michel, MD;²⁶⁹ Marios-Nikos Psychogios, MD;²⁶⁶ Davide Strambo, MD;²⁶⁹ Soma Banerjee, MD;²⁷⁰ Kailash Krishnan, MRCP PhD;²⁷¹ Joseph Kwan, MD MPhil FRCP;²⁷⁰ Asif Butt, MBBS;²⁷² Luciana Catanese, MD;²⁷³ Andrew Demchuk, MD;²⁷⁴ Thalia Field, MD MHSc;²⁷⁵ Jennifer Haynes, RN;²⁷⁶ Michael D Hill, MD MSc;²⁷⁴ Houman Khosravani, MD PhD;²⁷⁷ Ariane Mackey, MD;²⁷⁸ Aleksandra Pikula, MD;²⁷⁹ Gustavo Saposnik, MD MPH FRCPc;²⁸⁰ Courtney Anne Scott, MD;²⁷⁶ Ashkan Shoamanesh, MD;²⁷³ Ashfaq Shuaib, MD;²⁷² Samuel Yip, MD PhD;²⁷⁵ Miguel A Barboza, MD MSc;²⁸¹ Jose Domingo Barrientos, MD MSc;²⁸² Ligia Ibeth Portillo Rivera, MD;²⁸³ Fernando Gongora-Rivera, MD MSc;²⁸⁴ Nelson Navarro-Escudero, MD MSc;²⁸⁵ Anmylene Blanco, MD;²⁸⁵ Michael Abraham, MD;²⁸⁶ Diana Alsbrook, MD;²⁷ Dorothea Altschul, MD;²⁸⁷ Anthony J Alvarado-Ortiz, DO;²⁸⁸ Ivo Bach, MD;²⁸⁹ Aamir Badruddin, MD;²⁹⁰ Nobl Barazangi, MD PhD;²⁹¹ Charmaine Breerton, RN MSN;²⁹² Alicia Castonguay, PhD;²⁹³ Seemant Chaturvedi, MD;²⁹⁴ Saqib A. Chaudhry, MD;²⁹⁵ Hana Choe, MD;²⁹⁶ Jae H Choi, MD;²⁹⁷ Sushrut Dharmadhikari, MD;²⁹⁸ Kinjal Desai, MD MPH;²⁹⁹ Thomas G Devlin, MD PhD;³⁰⁰ Vinodh T Doss, MD;³⁰¹ Randall Edgell, MD;³⁰² Mark Etherton, MD PhD;³⁰³ Mudassir Farooqui, MBBS;³⁰⁴ Don Frei, MD;³⁰⁵ Dheeraj Gandhi, MD;³⁰⁶ Mikayel Grigoryan, MD;³⁰⁷ Rishi Gupta, MD;³⁰⁸ Ameer E Hassan, DO;³⁰⁹ Johanna Helenius, MD PhD;³¹⁰ Artem Kaliaev, MD;² Ritesh Kaushal, MD PhD;²⁸⁸ Priyank Khandelwal, MD;²⁸⁹ Ayaz M. Khawaja, MD;³¹¹ Naim N Khoury, MD MS;³¹² Benny S Kim, MD;³¹³ Dawn O. Kleindorfer, MD;³¹⁴ Feliks Koyfman, MD;³¹⁵ Vivien H. Lee, MD;³¹⁶ Lester Y Leung, MD MSc;³¹⁷ Guillermo Linares, MD;³¹⁸ Italo Linfante, MD;³¹⁹ Helmi L Lutsep, MD;³²⁰ Lisa Macdougall, RN MS;³²¹ Shailesh Male, MD;³²² Amer Malik, MD;³²³ Hesham Masoud, MD;³²⁴ Molly McDermott, MD;³¹⁴ Brijesh P Mehta, MD;³²⁵ Jiangyong Min, MD PhD;³²⁶ Manoj Mittal, MD;³²⁷ Jane G Morris, MD;³²⁸ Sumeet S Multani, MD;³²⁹ Fadi Nahab, MD;³³⁰ Krishna Nalleballe, MD;³³¹ Claude B Nguyen, MD;²⁹¹ Roberta Novakovic-White, MD;³³² Santiago Ortega-Gutierrez, MD;³⁰⁴ Rahul H Rahangdale, MD;³³³ Pankajavalli Ramakrishnan, MD PhD;³³⁴ Jose Rafael Romero, MD;³³⁵ Natalia Rost, MD;³⁰³ Aaron Rothstein, MD;³³⁶ Sean Ruland, DO;¹⁷ Ruchir Shah, MD;³⁰⁰ Malveeka Sharma, MD;³³⁷ Brian Silver, MD;³³⁸ Marc Simmons, MD;³²¹ Abhishek Singh, MD;³³⁹ Amy K Starosciak, PhD;³¹⁹ Sheryl L. Strasser, MD;³⁴⁰ Viktor Szeder, MD PhD;³⁴¹ Mohamed Teleb, MD;³⁴² Jenny P. Tsai, MD;³²⁶ Barbara Voetsch, MD PhD;³¹⁰ Oscar Balaguera, MD;³⁴³ Virginia A. Pujol Lereis, MD;³⁴⁴ Adriana Luraschi, MD;³⁴³ Marcele Schettini Almeida, MD;³⁴⁵ Fabricio Buchdid Cardoso, MD;³⁴⁶ Adriana Conforto, MD;³⁴⁵ Leonardo De Deus Silva, MD;³⁴⁷ Luidia Varrone Giacomini, MD;³⁴⁸ Fabricio Oliveira Lima, MD MPH PhD;³⁴⁹ Alexandre L Longo, MD;³⁵⁰ Pedro SC Magalhães, MD;³⁵⁰ Rodrigo Targa Martins, MD;³⁵¹ Francisco Mont'alverne, MD PhD;³⁴⁹ Daissy Liliana Mora Cuervo, MD;³⁵² Leticia Costa Rebello, MD;³⁵³ Lenise Valler, MD;³⁴⁶ Viviane Flumignan Zetola, MD PhD;³⁵⁴ Pablo M Lavados, MD MPH;³⁵⁵ Victor Navia, MD;³⁵⁶ Verónica V. Olavarría, MD;³⁵⁵ Juan Manuel Almeida Toro, MD;³⁵⁶ Pablo Felipe Ricardo Amaya, MD;³⁵⁷ Hernan Bayona, MD;³⁵⁸ Angel Basilio Corredor-Quintero, MD;³⁵⁹ Carlos Eduardo Rivera Ordóñez, MD;³⁶⁰ Diana Katherine Mantilla Barbosa, MD;³⁶¹ Osvaldo Lara, MD MSc;³⁶² Mauricio R. Patiño, MD;³⁶³ Luis Fernando Diaz Escobar, MD;³⁶⁴ Donoband Edson Dejesus Melgarejo Farina, MD;³⁶⁵ Analia Cardozo Villamayor, MD;³⁶⁵ Adolfo Javier Zelaya Zarza, MD;³⁶⁶ Danny Moises Barrientos Iman, MD;³⁶⁷ Liliana Rodriguez Kadota, MD;³⁶⁸ Bruce Campbell, MBBS PhD;³⁶⁹ Graeme J Hankey, MD;³⁷⁰ Casey Hair, RN;³⁷¹ Timothy Kleinig, MD PhD;³⁷² Alice Ma, MBBS;³⁷³ Rodrigo Tomazini Martins, MD, PhD;³⁷⁴ Ramesh Sahathevan, MD, PhD;³⁷¹ Vincent Thijs, MD;³⁷⁵ Daniel

Salazar, MD, PhD, FRACP;³⁷⁶ Teddy Yuan-Hao Wu, MD PhD;³⁷⁷ Diogo C. Haussen, MD;¹ David Liebeskind, MD;³⁷⁸ Dileep Yavagal, MD;³²³ Tudor G. Jovin, MD;¹⁵ Osama O Zaidat, MD;³⁷⁹ Thanh N. Nguyen, MD^{2,335} on behalf of the SVIN COVID-19 Global Stroke Registry

*Drs. Nogueira and Nguyen contributed equally to this article.

Corresponding Author: Thanh N. Nguyen thanh.nguyen@bmc.org

Affiliation Information for All Authors:

Department of Neurology, Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Emory University School of Medicine, Atlanta;¹ Department of Radiology, Boston Medical Center, Boston University School of Medicine, Boston, MA;² Radiation Oncology, Boston Medical Center;³ Department of Neurology, Federal University of Rio Grande do Sul, and Hospital de Clínicas de Porto Alegre, Brazil;⁴ Department of Stroke Neurology, National Hospital Organization, Osaka National Hospital, Japan;⁵ Department of Neurology, Xinqiao Hospital of the Army Medical University, Chongqing, China;⁶ Department of Neurology, Stroke and Neurointervention Division, Alexandria University Hospital, Alexandria University, Egypt;⁷ Boston University School of Medicine, Boston, MA;⁸ Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland;⁹ Department of Neurology, National & Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece;¹⁰ Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal;¹¹ Department of Neurology, Leuven University Hospital, Belgium;¹² International Clinical Research Center and Department of Neurology, St. Anne's University Hospital in Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;¹³ Department of Neurology, Groeninge Hospital, Kortrijk, Kortrijk, Belgium, Department of Neurology, University Hospitals Antwerp, Antwerp, Belgium, Department of Translational Neuroscience, University of Antwerp, Belgium;¹⁴ Department of Neurology, Cooper Neurological Institute, Cooper University Hospital, Camden, New Jersey;¹⁵ Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia;¹⁶ Department of Neurology, Loyola University Chicago Stritch School of Medicine, Chicago, IL, USA;¹⁷ Department of Neurosurgery, Kaiser Permanente Fontana Medical Center;¹⁸ Department of Neurology, Kaiser Permanente Los Angeles Medical Center;¹⁹ Department of Neurology, UT Health McGovern Medical School, Houston, Texas, USA;²⁰ Department of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA;²¹ Department of Internal Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece;²² Department of Neurology, Allegheny Health Network, Pittsburgh, PA, USA;²³ Department of Neurology, Ohio Health Doctors Hospital;²⁴ Department of Medicine and Neurology, University of Otago and Wellington Hospital, Wellington, New Zealand;²⁵ Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee;²⁶ Department of Neurology, University of Tennessee Health Center, Memphis;²⁷ Department of Neurology, University of North Carolina at Chapel Hill, North Carolina, USA;²⁸ Department of Neurology, New York University Grossman School of Medicine, New York, USA;²⁹ Department of Radiology, New York University Grossman School of Medicine, New York, USA;³⁰ Douala Gynaeco-Obstetric and Pediatric Hospital, University of Douala, Faculty of Medicine and Pharmaceutical Science, Cameroon;³¹ Ain Shams University Specialized Hospital, Egypt;³² Ain Shams University Hospital, Egypt;³³ Cairo University Affiliated MOH Network, Egypt;³⁴ Department of Neurology, Nasser Institute for Research and Treatment, Cairo;³⁵ Mansoura University Affiliated Private Hospitals Network,

Egypt;³⁶ Kwame Nkrumah University of Science and Technology, Kumasi, Ghana;³⁷ Stroke Unit, University of Ilorin Teaching Hospital, Nigeria;³⁸ Neurology Unit, Department of Medicine, Lagos State University Teaching Hospital, Nigeria;³⁹ Neurology Unit, Department of Medicine, Federal Medical Centre, Owerri, Nigeria;⁴⁰ Taofiki Ajao Sunmonu, MD, Neurology Unit, Department of Medicine, Federal Medical Centre, Owo, Ondo State, Nigeria;⁴¹ University College Hospital, Ibadan, Nigeria;⁴² The National Ribat University Affiliated Hospitals, Khartoum, Sudan;⁴³ Neurology Section, Department of Internal Medicine, Aga-Khan University, Medical College East Africa, Dar es Salaam, Tanzania;⁴⁴ Tunis El Manar University, Military Hospital of Tunis, Tunisia;⁴⁵ Department of Neurology, Mongi Ben Hmida National Institute of Neurology, Faculty of Medicine of Tunis, University Tunis El Manar;⁴⁶ Department of Physiology, Parirenyatwa Hospital, University of Zimbabwe;⁴⁷ Departments of Physiology and Medicine, University of Zimbabwe;⁴⁸ Department of Cerebrovascular / Endovascular Neurosurgery Division, Erebouni Medical Center, Yerevan, Armenia;⁴⁹ Department of Neurology, Sir Salimullah College, Dhaka, Bangladesh;⁵⁰ Department of Neurology, Taihe Hospital of Shiyuan City, Hubei, China;⁵¹ Department of Neurology, Nanyang Central Hospital, Henan, China;⁵² Department of Neurology, Wuhan No. 1 Hospital, Wuhan, Hubei, China;⁵³ Department of Neurology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang, China;⁵⁴ Department of Neurology, Traditional Chinese Medicine Hospital of Maoming, Guangdong, China;⁵⁵ Department of Neurology, Affiliated Hospital of Qingdao University, Shandong, China;⁵⁶ Department of Neurology, The First Affiliated Hospital of Hainan Medical College, Hainan, China;⁵⁷ Department of Neurology, Wuhan Central Hospital, Wuhan, Hubei, China;⁵⁸ Department of Neurology, Mianyang 404th Hospital, Sichuan, China;⁵⁹ Department of Neurology, Yijishan Hospital of Wannan Medical College, Anhui, China;⁶⁰ Department of Neurology and Neuroscience, Shenyang Brain Institute, Shenyang First People's Hospital, Shenyang Medical College Affiliated Brain Hospital, China;⁶¹ Department of Neurology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Shandong, China;⁶² Department of Neurology, Xiangyang Central Hospital, Hubei, China;⁶³ Department of Neurology, West China Hospital, Sichuan University, Chengdu, China;⁶⁴ Department of Neurology, West China Hospital, Sichuan University, Chengdu, China;⁶⁵ Department of Neurology, Affiliated Hospital of Southwest Medical University, Sichuan, China;⁶⁶ Department of Neurology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Zhejiang, China;⁶⁷ Department of Neurology, The First Affiliated Hospital of Shandong First Medical University, Shandong, China;⁶⁸ Department of Neurology, First Affiliated Hospital of Fujian Medical University, Fujian, China;⁶⁹ Acute Stroke Unit, The Prince of Wales Hospital, Kwok Tak Seng Centre for Stroke Research and Intervention, The Chinese University of Hong Kong, Hong Kong;⁷⁰ Interventional Neurology, MAX Superspecialty Hospital, Saket, New Delhi, India;⁷¹ NH Institute of Neurosciences, NH Mazumdar Shaw Medical Center, Bangalore, India;⁷² Department of Neurology, Apollo Speciality Hospitals Nellore, India;⁷³ Department of Neurology, Christian Medical College, Ludhiana, Punjab, India;⁷⁴ Sree Chitra Tirunal Institute for Medical Sciences and Technology, Kerala, India;⁷⁵ Stroke Unit, Pelni Hospital, Jakarta, Indonesia;⁷⁶ Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;⁷⁷ Beer Sheva Hospital, Israel;⁷⁸ Department of Interventional Neuroradiology, Rambam Health care Campus, Haifa, Israel;⁷⁹ Department of Neurology, Kobe City Medical Center General Hospital, Kobe, Japan;⁸⁰ Department of Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Japan;⁸¹ Department of Stroke and Neurovascular Surgery, IMS Tokyo-Katsushika General Hospital, Tokyo, Japan;⁸²

Yokohama Brain and Spine Center, Japan;⁸³ Iwate Prefectural Central, Japan;⁸⁴ Japanese Red Cross Kyoto Daiichi Hospital, Japan;⁸⁵ Department of Neurology, Kyoto Second Red Cross Hospital, Kyoto, Japan;⁸⁶ Department of Neurology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan;⁸⁷ Department of Stroke Neurology, Kohnan Hospital, Sendai, Japan;⁸⁸ Department of Cerebrovascular Medicine, Saga-Ken Medical Centre, Saga, Japan;⁸⁹ Department of Neurology, Saitama Medical Center, Kawagoe, Japan;⁹⁰ Department of Neurology, Nara City Hospital, Nara, Japan;⁹¹ Department of Neurology, Toyonaka Municipal Hospital, Osaka, Japan;⁹² Department of Neurology, Kagoshima City Hospital, Kagoshima, Japan;⁹³ Department of Neurology, Japanese Red Cross Matsue Hospital, Shimane, Japan;⁹⁴ Department of Neurology, Shiroyama Hospital, Osaka, Japan;⁹⁵ Department of Cerebrovascular Medicine, Niigata City General Hospital, Niigata, Japan;⁹⁶ Department of Neurology, Sugimura Hospital, Kumamoto, Japan;⁹⁷ Stroke Medicine, Kawasaki Medical School, Okayama, Japan;⁹⁸ Department of Neurology, Osaka Red Cross Hospital, Osaka, Japan;⁹⁹ Department of Stroke Prevention and Treatment, Department of Neurosurgery, University of Tsukuba, Ibaraki, Japan;¹⁰⁰ Department of Neurology, Stroke Center and Neuroendovascular Therapy, Saiseikai Central Hospital, Tokyo, Japan;¹⁰¹ Department of Neurology, Kin-ikyo Chuo Hospital, Hokkaido, Japan;¹⁰² Department of Cerebrovascular Medicine, NTT Medical Center Tokyo, Japan;¹⁰³ Department of Neurology and Neuroendovascular Treatment, Yokohama Shintoshin Neurosurgical Hospital, Yokohama, Japan;¹⁰⁴ Department of Neurology, Osaka General Medical Center, Japan;¹⁰⁵ Department of Neurology, Osaka University Hospital, Japan;¹⁰⁶ Department of Advanced Brain Research, Tokushima University Hospital Tokushima, Japan;¹⁰⁷ Department of Neurology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan;¹⁰⁸ Department of Neurology, Tane General Hospital, Osaka, Japan;¹⁰⁹ Division of Stroke, Department of Internal Medicine, Osaka Rosai Hospital, Osaka, Japan;¹¹⁰ Department of Comprehensive Stroke, Fujita Health University School of Medicine, Toyoake, Japan;¹¹¹ Department of Neurology, Asfendiyarov Kazakh National Medical University, Kazakhstan;¹¹² Republican Center for eHealth, Ministry of Health of the Republic of Kazakhstan;¹¹³ Al-Farabi Kazakh National University, Department of Medicine, Kazakhstan;¹¹⁴ Kazakh-Russian Medical University, Kazakhstan;¹¹⁵ Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea;¹¹⁶ Department of Neurology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, South Korea;¹¹⁷ Ajou University Hospital, South Korea;¹¹⁸ Department of Neurology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, South Korea;¹¹⁹ Department of Neurology, National Medical Center, Seoul, South Korea;¹²⁰ Department of Neurology, Keimyung University School of Medicine, Dongsan Medical Center, Daegu, South Korea;¹²¹ Department of Neurology, Busan Paik Hospital, School of Medicine, Inje University, Busan, South Korea;¹²² Department of Neurology, National Health Insurance Service Ilsan Hospital, Goyang, South Korea;¹²³ Asan Medical Center, Seoul, Korea;¹²⁴ Department of Neurology, LAU Medical Center-Rizk Hospital, Beirut, Lebanon;¹²⁵ Department of Medicine, Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia;¹²⁶ Sultanah Nur Zahirah, Kuala Terengganu, Malaysia;¹²⁷ University Putra Malaysia;¹²⁸ Sarawak General Hospital, Kuching, Malaysia;¹²⁹ Hospital Sultan Abdul Halim, Sungai Petani Kedah, Malaysia;¹³⁰ Hospital Seberang Jaya, Pulau Pinang, Malaysia;¹³¹ Thomson Hospital Kota Damansara, Malaysia;¹³² "Nicolae Testemitanu" State University of Medicine and Pharmacy, Chisinau, Republic of Moldova, Department of Neurology Department, Emergency Medicine Institute, Chisinau, Republic of Moldova;¹³³ Department of Stroke Unit, Royal Hospital Muscat, Oman;¹³⁴ Neuroscience Institute, Hamad Medical Corporation, Doha,

Qatar;¹³⁵ St. Luke's Medical Center – Institute of Neurosciences, Philippines;¹³⁶ Endovascular Neurosurgery, Saint-Petersburg Dzhanelidze Research Institute of Emergency Medicine, St. Petersburg, Russia;¹³⁷ Department of Neurology, Stroke Unit, King Saud University, College of Medicine, Riyadh, Saudi Arabia;¹³⁸ Department of Neurosurgery, Interventional Radiology, and Critical Care Medicine, King Fahad Hospital of the University, Imam Abdulrahman bin Faisal University, Saudi Arabia;¹³⁹ Singapore National Neuroscience Institute, Singapore;¹⁴⁰ Changi General Hospital, Singapore;¹⁴¹ Neuroscience Center, Raffles Hospital, Singapore;¹⁴² Department of Neurology, National Taiwan University Hospital, Taiwan;¹⁴³ Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand;¹⁴⁴ Dicle University Medical School and Hospital, Diyarbakir, Turkey;¹⁴⁵ Stroke and Neurointervention Unit, Eskisehir Osmangazi University, Turkey;¹⁴⁶ Gaziantep University Faculty of Medicine, Turkey;¹⁴⁷ Department of Neurology, Neurological Institute at Cleveland Clinic Abu Dhabi, United Arab Emirates;¹⁴⁸ Stroke Center, Hue Central Hospital, Hue, Vietnam;¹⁴⁹ Stroke Department, Da Nang Hospital, Da Nang City, Vietnam;¹⁵⁰ 115 People's Hospital, Vietnam;¹⁵¹ Department of Neurology, Medical University of Graz, Austria;¹⁵² Neurology, Research Institute of Neurointervention, University Hospital Salzburg / Paracelsus Medical University, Salzburg, Austria;¹⁵³ Department of Neurology, Centre Hospitalier de l'Université Charleroi, Belgium;¹⁵⁴ Department of Neurology, Sint Jan Hospital, Bruges, Belgium;¹⁵⁵ Department of Neurology, Brussels University Hospital (UZ Brussel), Belgium;¹⁵⁶ Department of Neurology, Centre Hospitalier Universitaire de Charleroi, Belgium;¹⁵⁷ Department of Neurology, ULB Erasme Hospitals Brussels, Brussels, Belgium;¹⁵⁸ Department of Neurology, Europa Hospitals Brussels, Brussels, Belgium;¹⁵⁹ Department of Neurology, Antwerp University Hospital, Antwerp, Belgium;¹⁶⁰ Neurology Clinic, St. Anna University Hospital, Sofia, Bulgaria;¹⁶¹ Department of Neurology, Sestre Milosrdnice University Hospital, Zagreb, Croatia;¹⁶² Department of Neurology, Sveti Duh University Hospital, Zagreb, Croatia;¹⁶³ Department of Neurology, General Hospital Virovitica, Croatia;¹⁶⁴ Department of Neurology, General Hospital Zabok, Croatia;¹⁶⁵ Department of Radiology, University Hospital Centre Zagreb, Croatia;¹⁶⁶ Regional Hospital Karlovy Vary, Czech Republic;¹⁶⁷ Masaryk Hospital Usti nad Labem, Czech Republic;¹⁶⁸ Military University Hospital Praha, Czech Republic;¹⁶⁹ Oblastní Nemocnice Náchod, Czech Republic;¹⁷⁰ Regional Hospital Pribram, Czech Republic;¹⁷¹ Municipal Hospital Ostrava, Czech Republic;¹⁷² Hospital Mlada Boleslav, Czech Republic;¹⁷³ Hospital Vitkovice, Czech Republic;¹⁷⁴ Hospital Jihlava, Czech Republic;¹⁷⁵ General University Hospital Praha, Czech Republic;¹⁷⁶ Hospital Litomyšl, Czech Republic;¹⁷⁷ Hospital České Budejovice, Czech Republic;¹⁷⁸ Hospital Pisek, Czech Republic;¹⁷⁹ Hospital Uherske Hradiste, Czech Republic;¹⁸⁰ Hospital Prostějov, Czech Republic;¹⁸¹ Regional Hospital Chomutov, Czech Republic;¹⁸² Hospital Teplice, Czech Republic;¹⁸³ Mining Hospital Karvina, Czech Republic;¹⁸⁴ Thomayer Hospital Praha, Czech Republic;¹⁸⁵ Hospital Blansko, Czech Republic;¹⁸⁶ University Hospital Brno, Czech Republic;¹⁸⁷ Regional Hospital Liberec, Czech Republic;¹⁸⁸ Hospital Ceska Lipa, Czech Republic;¹⁸⁹ Hospital Sokolov, Czech Republic;¹⁹⁰ Regional Hospital Kolin, Czech Republic;¹⁹¹ Hospital Trutnov, Czech Republic;¹⁹² Hospital Trinec, Czech Republic;¹⁹³ Department of Neurology, University Hospital Ostrava, Faculty of Medicine, Masaryk University, Brno, Czech Republic;¹⁹⁴ Bispebjerg Hospital, University of Copenhagen, Denmark;¹⁹⁵ Bispebjerg Hospital, University of Copenhagen, Denmark;¹⁹⁵ Stroke Center, Rigshospitalet, University of Copenhagen, Denmark;¹⁹⁶ Aarhus University Hospital, Aarhus, Denmark;¹⁹⁷ Sjaelland University Hospital, Zealand University Hospital, Roskilde, Denmark;¹⁹⁸ Neurology Clinic, West Tallinn Central Hospital, Tallinn, Estonia;¹⁹⁹ Center of Neurology, East

Tallinn Central Hospital, School of Natural Sciences and Health, Tallinn University, Tallinn, Estonia;²⁰⁰ Internal Medicine Clinic, Pärnu Hospital, Pärnu, Estonia;²⁰¹ Université Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, Lille, France;²⁰² Centre Hospitalier d'Arcachon, Gujan-Mestras, France;²⁰³ Centre Hospitalier d'Agen, Agen, France;²⁰⁴ Neurologie Vasculaire, Hospices Civils de Lyon, Hôpital Pierre Wertheimer, Bron, France;²⁰⁵ Neuroradiologie, Hospices Civils de Lyon, Hôpital Pierre Wertheimer, Bron, France;²⁰⁶ Centre Hospitalier et Universitaire de Bordeaux;²⁰⁷ Centre Hospitalier de Mont de Marsan, France;²⁰⁸ Neurologie, Fondation Ophtalmologique Adolphe de Rothschild, France;²⁰⁹ Versailles Saint-Quentin-en-Yvelines University, Versailles, France;²¹⁰ Neuroradiologie Interventionnelle, Fondation Ophtalmologique Adolphe de Rothschild, France;²¹¹ Neuroradiologie Interventionnelle, Hôpitaux Universitaires de Strasbourg, France;²¹² K.Eristavi National Center of Experimental and Clinical Surgery, Tbilisi, Georgia;²¹³ Department of Neurosurgery, New Vision University Hospital, Tbilisi, Georgia and Vivamedi Medical Center, Georgia;²¹⁴ Pineo Medical Ecosystem, Tbilisi, Georgia;²¹⁵ Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia;²¹⁶ Department of Neurology, University Hospital Heidelberg, Germany;²¹⁷ Department of Neurology, Albertinen Krankenhaus, Hamburg, Germany;²¹⁸ Department of Neurology, Elbe Klinken Stade, Stade, Germany, University Medical Center Göttingen, Germany;²¹⁹ Department of Neurology, University Hospital Carl Gustav Carus, Dresden, Germany;²²⁰ Kristina Szabo, MD, Department of Neurology, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany;²²¹ Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Germany;²²² Department of Internal Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece;²²³ Second Department of Neurology, Stroke Unit, Metropolitan Hospital, Piraeus, Greece;²²⁴ University of Szeged, Szeged, Hungary;²²⁵ University of Pecs, Hungary;²²⁶ Stroke Center, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, Negrar, Verona, Italy;²²⁷ Department of Neurology, Ospedale San Paolo, Savona, Italy;²²⁸ Institute of Neurology, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy;²²⁹ Interventional Neurovascular Unit, Careggi University Hospital, Florence, Italy;²³⁰ Stroke Unit, Azienda Socio Sanitaria Territoriale (ASST) di Lecco, Italy;²³¹ Maastricht University Medical Center;²³² Department of Neurology, Radiology, University Medical Center Groningen, Groningen;²³³ Department of Neurology, Haaglanden Medical Center, the Hague, the Netherlands;²³⁴ Department of Neurology, Akershus University Hospital, Lørenskog, General Practice, HELSAM, University of Oslo, Oslo, Norway;²³⁵ Neurological Ward with Stroke Unit, Specialist Hospital in Koneskie, Gimnazjalna, Poland;²³⁶ Neurological Ward with Stroke Unit, District Hospital in Skarzysko-Kamienna, Poland;²³⁷ Department of Neurology, Szpitala im. T. Marciniaka in Wrocław, Poland;²³⁸ 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland;²³⁹ Department of Neurology and Cerebrovascular Disorders, Poznan University of Medical Sciences, Poznan, Poland;²⁴⁰ 107th Military Hospital with Polyclinic, Walcz, Poland;²⁴¹ Department of Neurology, St. Queen Jadwiga, Clinical Regional Hospital No. 2, Rzeszow, Poland;²⁴² Department of Neurology, Medical University of Lublin, Lublin, Poland;²⁴³ 1st Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland;²⁴⁴ Department of Neurology and Stroke Unit, Holy Spirit Specialist Hospital in Sandomierz, Collegium Medicum Jan Kochanowski University in Kielce, Poland;²⁴⁵ Copernicus PL, Neurology and Stroke Department, Hospital M. Kopernik, Gdansk, Poland;²⁴⁶ Stroke Unit, Neurological Department, Stanislaw Staszic University of Applied Sciences, Pila, Poland;²⁴⁷ Hospital São José, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal;²⁴⁸ Stroke Unit, Hospital Pedro Hispano, Matosinhos;²⁴⁹ Department of Neurology, Neuroradiology

Department, Centro Hospitalar Universitário de São João, Porto, Portugal;²⁵⁰ Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal;²⁵¹ Department of Neurosciences, Hospital de Santa Maria-CHLN, North Lisbon University Hospital, Lisbon, Portugal;²⁵² Hospital São José, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal;²⁵³ Department of Neurology, Hospital Garcia de Orta, Portugal;²⁵⁴ Department of Neurology, Transilvania University, Brasov, Romania;²⁵⁵ Department of Neurology, Faculty Hospital Trnava, Slovakia;²⁵⁶ Department of Neurology and Stroke Center, Hospital Universitario La Paz, Madrid, Spain;²⁵⁷ Department of Neurology, Hospital Clínico Universitario, Universidad de Valladolid, Valladolid, Spain;²⁵⁸ Department of Neurology, Complejo Hospitalario Universitario de Albacete, Spain;²⁵⁹ Department of Neurology, Unidad de Ictus. Hospital Universitario Ramon y Cajal, Madrid, Spain;²⁶⁰ Department of Neurology, Hospital Universitario Virgen Macarena & Neurovascular Research Laboratory, Instituto de Biomedicina de Sevilla-IbiS, Seville, Spain;²⁶¹ Rio Hortega University Hospital. University of Valladolid;²⁶² Cerebrovascular Diseases, Hospital Clinic of Barcelona, Spain;²⁶³ Department of Neurology, Karolinska University Hospital and Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden;²⁶⁴ Department of Interventional Neuroradiology, University Hospitals of Geneva, Switzerland;²⁶⁵ Department of Interventional and Diagnostic Neuroradiology, Radiology and Nuclear Medicine, University Hospital Basel, Switzerland;²⁶⁶ Department of Neurology, University of Bern, Bern, Switzerland;²⁶⁷ Department of Neuroradiology, University of Bern, Bern, Switzerland;²⁶⁸ Department of Neuroscience, Lausanne University Hospital, Lausanne, Switzerland;²⁶⁹ Department of Stroke Medicine, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK;²⁷⁰ Department of Neurology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, United Kingdom;²⁷¹ Department of Neurology, University of Alberta, Edmonton, Canada;²⁷² Department of Neurology, McMaster University, Hamilton, Canada;²⁷³ Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Canada;²⁷⁴ Department of Neurology, University of British Columbia, Vancouver, British Columbia, Canada;²⁷⁵ Mackenzie Health;²⁷⁶ Department of Neurology, Sunnybrook Health Sciences Centre, University of Toronto, Canada;²⁷⁷ Department of Neurology, Hopital Enfant Jesus, Centre Hospitalier de l'Université Laval, Quebec City, Canada;²⁷⁸ Department of Neurology, University of Toronto, Canada;²⁷⁹ Medicine, St. Michael's Hospital, University of Toronto, Canada;²⁸⁰ Department of Neurosciences, Hospital Dr. Rafael A. Calderon Guardia, CCSS. San Jose, Costa Rica;²⁸¹ Neurovascular Service, Hospital General San Juan de Dios, Guatemala City;²⁸² Department of Neurología, Hospital General de Enfermedades, Instituto Guatemalteco de Seguridad Social, Guatemala;²⁸³ Department of Neurology, University Hospital Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Mexico;²⁸⁴ Pacífica Salud – Hospital Punta Pacífica, Panama;²⁸⁵ Department of Neurology, Radiology, University of Kansas Medical Center, Kansas;²⁸⁶ Department of Neurointerventional Neurosurgery, Valley Baptist;²⁸⁷ Palmetto General Hospital, Tenet, Florida, USA;²⁸⁸ Neurology, University Hospital Newark, New Jersey Medical School, Rutgers, Newark, NJ, USA;²⁸⁹ Community Healthcare System, Munster, Indiana;²⁹⁰ Department of Neurology, California Pacific Medical Center, CA;²⁹¹ Department of Neurology, Mount Sinai South Nassau, New York, USA;²⁹² University of Toledo, Ohio, USA;²⁹³ Department of Neurology, University of Maryland School of Medicine, USA;²⁹⁴ Neuroscience, Inova Fairfax Hospital, Virginia;²⁹⁵ Department of Neurology, Abington Jefferson Hospital, Pennsylvania;²⁹⁶ Department of Neurology, Mount Sinai South Nassau, New York, USA;²⁹⁷ Baptist Health Medical Center, Little Rock, Arkansas, USA;²⁹⁸ Department of Neurology, HCA

Houston Healthcare Clearlake, Texas, USA;²⁹⁹ Department of Neurology, Erlanger, Tennessee, USA;³⁰⁰ Wilmington North Carolina;³⁰¹ Department of Vascular and Neurointerventional Services, St. Louis University³⁰²; Department of Neurology, Massachusetts General Hospital, Boston, USA;³⁰³ Department of Neurology, Neurosurgery, and Radiology, University of Iowa Hospitals and Clinics, USA;³⁰⁴ Department of Radiology, Swedish Medical Center, Englewood, Colorado, USA;³⁰⁵ Department of Radiology, Neurosurgery, University of Maryland School of Medicine, USA;³⁰⁶ Adventist Health Glendale Comprehensive Stroke Center, Los Angeles, CA, USA;³⁰⁷ Wellstar Neuroscience Institute, Marietta, Georgia, USA;³⁰⁸ Department of Neurology, University of Texas Rio Grande Valley-Valley Baptist Medical Center, Texas, USA;³⁰⁹ Department of Neurology, Lahey Hospital & Medical Center, Beth Israel Lahey Health, Burlington, USA;³¹⁰ Department of Neurology, Wayne State, Detroit, USA;³¹¹ HSHS St. John's Hospital, Southern Illinois University School of Medicine, Springfield, USA;³¹² Virginia Hospital Center, USA;³¹³ Department of Neurology, University of Michigan, USA;³¹⁴ Weill-Cornell Medical College, New York-Presbyterian Queens, New York, USA;³¹⁵ Department of Neurology, Ohio State University, USA;³¹⁶ Department of Neurology, Tufts Medical Center, Boston, USA;³¹⁷ Vascular and Neurointerventional Services, St. Louis University;³¹⁸ Vascular Institute, Florida, USA;³¹⁹ Department of Neurology, Oregon Health & Science University, USA;³²⁰ Department of Emergency Medicine, Steward Holy Family Hospital, MA, USA;³²¹ Vidant Medical Center, Greenville, North Carolina;³²² Department of Neurology, University of Miami Miller School of Medicine, Florida, USA;³²³ Department of Neurology, SUNY Upstate New York, USA;³²⁴ Memorial Neuroscience Institute, Pembroke Pines, Florida, USA;³²⁵ Neurosciences, Spectrum Health, Michigan State University College of Medicine, Grand Rapids, MI;³²⁶ Sutter Health, Sacramento, California;³²⁷ Department of Neurology, Maine Medical Center, Portland, Maine, USA;³²⁸ Department of Neurology, Bayhealth, Dover, Delaware, USA;³²⁹ Department of Neurology, Grady Memorial Hospital, Emory University, Atlanta, Georgia, USA;³³⁰ Department of Neurology, University of Arkansas for Medical Sciences, USA;³³¹ Department of Radiology and Neurology, UT Southwestern Medical Center, Dallas, Texas, USA;³³² Ascension St. John Medical Center, Tulsa Oklahoma, USA;³³³ Riverside Regional Medical Center, Newport, Virginia, USA;³³⁴ Department of Neurology, Boston University School of Medicine, Boston, MA, USA;³³⁵ Department of Neurology, Hospital of the University of Pennsylvania, USA;³³⁶ Department of Neurology, University of Washington School Medicine, Seattle, USA;³³⁷ Department of Neurology, University of Massachusetts Medical Center, Worcester, MA, USA;³³⁸ Department of Neurology, CHI-Immanuel Neurological Institute, Creighton University, Omaha, Nebraska, USA;³³⁹ Holy Cross Hospital, Fort Lauderdale, Florida, USA;³⁴⁰ Department of Neurology, Interventional Neuroradiology, University of California in Los Angeles, Los Angeles, USA;³⁴¹ Banner Desert Medical Center, AZ USA;³⁴² Hospital de Agudos Dr. Ignacio Privano, Argentina;³⁴³ Institute for Neurological Research, FLENI, Buenos Aires, Argentina;³⁴⁴ Hospital das Clinicas / Sao Paulo University, Brazil;³⁴⁵ Sumare State Hospital, Brazil;³⁴⁶ Hospital Vera Cruz, Deus Campinas, Brazil;³⁴⁷ Irmanandade Santa Casa de Porto Alegre, Brazil;³⁴⁸ Stroke Unit, Hospital Geral de Fortaleza, Fortaleza-CE, Brazil;³⁴⁹ Stroke Unit, Hospital Sao Jose, Joinville, Santa Catarina, Brazil;³⁵⁰ Stroke Unit, Neurology, Nossa Senhora da Conceição Hospital, Porto Alegre, Brazil;³⁵¹ Department of Neurology, Hospital Moinhos de Vento, Porto Alegre, Brazil;³⁵² Department of Neurology, Hospital de Base do Distrito Federal, Brazil;³⁵³ Hospital Ana, Hospital Juliane, Federal University of Parana, Curitiba, Brazil;³⁵⁴ Vascular Neurology Unit, Neurology Service, Department of Neurology and Psychiatry, Clínica Alemana, Universidad del Desarrollo,

Santiago, Chile;³⁵⁵ Hospital Padre Hurtado. Santiago, Chile;³⁵⁶ Fundación Valle del Lili, Cali, Colombia;³⁵⁷ Stroke Center, Fundación Santa Fe, Colombia;³⁵⁸ Department of Neurology, Hospital Departamental Universitario del Quindío San Juan de Dios, Armenia, Colombia;³⁵⁹ Clínica Universitaria Colombia, Colombia;³⁶⁰ University Hospital of San Vicente Foundation, Medellín, Colombia;³⁶¹ Barranquilla, Colombia;³⁶² Hospital Infantil Universitario de San José, Bogotá, Colombia;³⁶³ Stroke Unit, Hospital de Clínicas, Facultad de Ciencias Médicas, Universidad Nacional de Asunción, Colombia;³⁶⁴ Neurology Service, Hospital Central del Instituto de Previsión Social, Colombia;³⁶⁵ Internal Medicine Service, Hospital Central de Policía “Rigoberto Caballero”, Colombia;³⁶⁶ National Institute of Neurological Sciences of Lima Peru;³⁶⁷ Hospital Edgardo Rebagliati Martins Lima-Peru;³⁶⁸ Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia;³⁶⁹ Department of Neurology, Sir Charles Gairdner Hospital, The University of Western Australia, Perth, Australia;³⁷⁰ University of Melbourne, Ballarat Health Service, Australia University of Melbourne, Australia;³⁷¹ Department of Neurology, Royal Adelaide Hospital, Adelaide, Australia;³⁷² Department of Neurosurgery, Royal North Shore Hospital, Sydney, Australia;³⁷³ Department of Neurology, Mater Hospital and Health Care, Brisbane, Australia;³⁷⁴ Department of Neurology, Austin Health, Victoria, Australia and Florey Institute of Neuroscience and Mental Health;³⁷⁵ Greymouth Base Hospital, Greymouth, New Zealand;³⁷⁶ Department of Neurology, Christchurch Hospital, Christchurch, New Zealand;³⁷⁷ Department of Neurology, University of California in Los Angeles, Los Angeles, USA;³⁷⁸ Department of Neurology, Mercy Health Neurosciences, USA;³⁷⁹

Number of characters in title: 77

Abstract Word count: 241

Word count of main text: 3002

References: 27

Figures: 2

Tables: 5

Statistical Analysis performed by: Muhammad M. Qureshi, MPH Boston University School of Medicine

Study Funding: The authors report no targeted funding

Disclosure: Dr. Nogueira reports consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Imperative Care, Medtronic, Phenox, Prolong Pharmaceuticals, Stryker Neurovascular and stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, and Perfuze. Dr. Martins reports receiving lecture fees from Bayer, Medtronic, Penumbra and speaker / advisory board fees from Boehringer Ingelheim. Dr. Czlonkowska reports service as Expert Witness. Dr. Siegler served as a Consultant for Ceribell. The institution of Dr. Siegler has received research support from NIH. The institution of Dr. Czap has received research support from National Institutes of Health. Dr. Holmstedt served as a Consultant for Astrazeneca. The institution of Dr. Holmstedt has received research support from NIH. The institution of Dr. Holmstedt has received research support from Patient-Centered Outcomes Research Institute. The institution of Dr. Holmstedt has received research support from CSPC Pharmaceuticals. Dr. Holmstedt served as a Study Adjudicator with Ischemia Care. Dr. Turan served on a Scientific Advisory or DSMB for Pfizer/Merck. Dr. Turan

served on a Scientific Advisory or DSMB for Gore Inc. Dr. Turan has received publishing royalties from a publication relating to health care. Dr. Alexandrov served on a Speakers Bureau for Genentech. The institution of Dr. Alexandrov has received research support from National Institutes of Health. Dr. Huang served on a Scientific Advisory or DSMB for ReNeuron. Dr. Huang served on a Scientific Advisory or DSMB for KMPHC. Dr. Raz served as an Expert Witness for Law firms. Eytan Raz has received publishing royalties from a publication relating to health care. Dr. Sheth served as a Consultant for Penumbra. Dr. Sheth served as a Consultant for Cerenovus. The institution of Dr. Frankel has received research support from Nico Corporation, Inc. Dr. Rahman served as a Consultant for Ministry of Health and family Planning, Bangladesh. Dr. Rahman has received research support from Ministry of Science and Technology, Bangladesh. Dr. Rahman has received publishing royalties from a publication relating to health care. The institution of Dr. PN Sylaja, 10063 has received research support from Sree Chitra Tirunal Institute for Medical Sciences and Technology. Dr. Mehdi Farhoudi served as an officer or member of the Board of Directors for Kenes. Dr. Elyar Sadeghi Hokmabadi served on a Speakers Bureau for ArvandPharmed. Dr. Elyar Sadeghi Hokmabadi served on a Speakers Bureau for Osve pharmaceutical company. The institution of Dr. Nobuyuki Sakai has received research support from DaiichiSankyo. The institution of Dr. Sakai has received research support from Terumo. Dr. Sakai served as a lecture honorarium with Asahi Intec. Dr. Yagita served on a Scientific Advisory or DSMB for Shionogi. Dr. Yagita served on a Speakers Bureau for Daiichi-Sankyo. Dr. Yagita served on a Speakers Bureau for Eisai. Dr. Yagita served on a Speakers Bureau for Bristol-Myers Squibb. Dr. Yagita served on a Speakers Bureau for abbvie. Dr. Yagita served on a Speakers Bureau for astellas. Dr. Yagita served on a Speakers Bureau for pfizer. Dr. Yagita served on a Speakers Bureau for Otsuka. Dr. Yagita served on a Speakers Bureau for Sumitomo Dainippon. Dr. Yagita served on a Speakers Bureau for Mitsubishi Tanabe. Dr. Yagita served on a Speakers Bureau for Kowa. Dr. Yagita served on a Speakers Bureau for Bayer. Dr. Yagita served on a Speakers Bureau for KYOWA KIKAKU. The institution of Dr. Yagita has received research support from Takeda. Dr. Matsumaru served on a Speakers Bureau for Medtronic. Dr. Matsumaru served on a Speakers Bureau for Stryker. Dr. Matsumaru served on a Speakers Bureau for Terumo. Dr. Matsumaru served on a Speakers Bureau for J&J. Dr. Matsumaru served on a Speakers Bureau for Kaneka. The institution of Dr. Todo has received research support from JSPS KAKENHI Grant Number 20K07885. Dr. Todo served as a lecturer with Medtronic. Dr. Todo served as a lecturer with Bristol-Myers Squibb. Dr. Todo served as a lecturer with Pfyzer. Dr. Todo served as a lecture with Byer. Dr. Todo served as a lecturer with Daiichi Sankyo. Dr. Todo served as a lecture with Stryker. The institution of Dr. Sonoda has received research support from The Ministry of Education, Culture, Sports, Science and Technology; Japan. Dr. Asyraf Dr. Zaidi served as a Consultant for Boehringer Ingelheim. Dr. Asyraf Dr. Zaidi served as a Consultant for Medtronic. The institution of Dr. Asyraf Dr. Zaidi has received research support from The George Institute. The institution of Dr. Asyraf Dr. Zaidi has received research support from The Florey Institute of Neuroscience and Mental Health. Dr. Al-Jehani served as an Editor, Associate Editor, or Editorial Advisory Board Member for Boehringer Ingelheim. Dr. Chen has received research support from Ministry of Science and Technology. The institution of Dr. Gattringer has received research support from Austrian Neurological Society. Dr. Killer-Oberpfalzer served as a Consultant for Medtronic. The institution of Dr. Killer-Oberpfalzer served as a Consultant for Microvention. Dr. Vanhooren served as a Consultant for BAYER. Dr. Pierre Rutgers served on a Scientific Advisory or DSMB

for Novartis. Dr. Pierre Rutgers served on a Scientific Advisory or DSMB for Daiichi Sankyo. Dr. Pierre Rutgers served on a Scientific Advisory or DSMB for Bayer. Dr. Pierre Rutgers served on a Scientific Advisory or DSMB for Boehringer Ingelheim. Dr. Pierre Rutgers served on a Scientific Advisory or DSMB for Piramal Imaging Limited. Dr. Budincevic served on a Scientific Advisory or DSMB for Boehringer Ingelheim. Dr. Budincevic served on a Speakers Bureau for Bayer. The institution of Dr. Budincevic has received research support from Novo Nordisk. Dr. Klecka served as a Consultant for Novartis s.r.o.. Dr. Klecka served on a Scientific Advisory or DSMB for Novartis. Dr. Klecka served on a Scientific Advisory or DSMB for Teva. The institution of Dr. Hlinovsky has received research support from AstraZeneca. Dr. Klingenberg Iversen served on a Scientific Advisory or DSMB for BAYER. Dr. Klingenberg Iversen served on a Scientific Advisory or DSMB for Boehringer Ingelheim. Dr. Klingenberg Iversen served as an officer or member of the Board of Directors for Danish Stroke Society. Dr. Klingenberg Iversen has received publishing royalties from a publication relating to health care. The institution of Dr. Simonsen has received research support from Novo Nordisk Foundation. Dr. Gross-Paju served on a Scientific Advisory or DSMB for Sanofi Genzyme. Dr. Gross-Paju served on a Scientific Advisory or DSMB for Novartis. Dr. Gross-Paju served on a Speakers Bureau for Merck. Dr. Cordonnier served on a Scientific Advisory or DSMB for Biogen (steering committee). Dr. Cordonnier served on a Scientific Advisory or DSMB for BMS (steering committee). Dr. Cordonnier served on a Speakers Bureau for Boehringer-Ingelheim. Dr. Cordonnier served as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke journal. The institution of Dr. Cordonnier has received research support from French ministry of health. Dr. EKER served as a Consultant for CERENOVUS Dr. Ondze served as a Consultant for NOVARTIS. Dr. Fernando Pico served on a Speakers Bureau for Boehringer. Dr. Krishnan has served on the Speakers Bureau for Daiichi Sankyo. Dr. Nagel served as a Consultant for Brainomix. Dr. Nagel served on a Speakers Bureau for Böhringer Ingelheim. Dr. Nagel served on a Speakers Bureau for BMS Pfizer. Dr. Ringleb served on a Scientific Advisory or DSMB for Boehringer Ingelheim. Dr. Ringleb served on a Speakers Bureau for Boehringer Ingelheim. Dr. Ringleb served on a Speakers Bureau for Bayer. Dr. Ringleb served on a Speakers Bureau for Daiichi Sankyo. Dr. Ringleb served on a Speakers Bureau for Pfizer. The institution of Dr. Schmidt has received research support from Biomerieux. The institution of Dr. Schmidt has received research support from GBA, German Fed. Government. Dr. Schmidt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schmidt served as a Examiner with Board of Physicians Lower Saxony. The institution of Dr. Siepmann has received research support from German Federal Ministry of Health. Dr. Siepmann has received publishing royalties from a publication relating to health care. Dr. Szabo has received research support from Ministry of Science and Research, Baden-Württemberg, Germany. Dr. Szabo has received publishing royalties from a publication relating to health care. Dr. Thomalla served as a Consultant for Acandis. Dr. Thomalla served as a Consultant for Stryker. Dr. Thomalla served as a Consultant for Portola. Dr. Thomalla served on a Speakers Bureau for Daiichi Sankyo. Dr. Thomalla served on a Speakers Bureau for Bristol Myers Squibb / Pfizer. Dr. Klivenyi served as a Consultant for BIOGEN. Dr. Klivenyi served as a Consultant for Abbvie. Dr. Karlinski, served as a Consultant for Boehringer Ingelheim. Dr. Karlinski, served on a Scientific Advisory or DSMB for Boehringer Ingelheim. Dr. Karlinski, served on a Scientific Advisory or DSMB for Bayer. Dr. Karlinski, served on a Scientific Advisory or DSMB for Medtronic. Dr. Karlinski, served on a Speakers Bureau for Boehringer Ingelheim. Dr. Karlinski, served on a Speakers Bureau for Bayer. Dr. Karlinski, served on a Speakers Bureau

for Medtronic. Dr. Halina Sienkiewicz-Jarosz, PhD served on a Speakers Bureau for Servier. Halina Sienkiewicz-Jarosz, PhD served on a Speakers Bureau for Medical Tribune. The institution of Halina Sienkiewicz-Jarosz, PhD has received research support from The National Centre for Research and Development. Dr. Fryze served as a Consultant for Roche, Merck, Biogen. Dr. Fryze served on a Speakers Bureau for Roche, Merck, Novartis. Dr. Fryze has received research support from Roche, Merck, Biogen, Alkermes, AstraZeneca, Bayer, Actelion. Dr. Arenillas has served as a Consultant for Bayer. Dr. Arenillas served as a Consultant for Boehringer-Ingelheim. Dr. Arenillas served as a Consultant for Daiichi-Sankyo. Dr. Arenillas served as a Consultant for Amgen. Dr. Arenillas served as a Consultant for Pfizer. Dr. Arenillas served on a Scientific Advisory or DSMB for AstraZeneca. Dr. Arenillas served on a Scientific Advisory or DSMB for Amgen. Dr. Arenillas served on a Scientific Advisory or DSMB for Fundació Ictus Barcelona. Dr. Arenillas served on a Speakers Bureau for Daiichi-Sankyo. Dr. Arenillas served on a Speakers Bureau for Bayer. Dr. Arenillas served on a Speakers Bureau for Boehringer. The institution of Dr. Arenillas has received research support from Carlos III Health Institute, Madrid, Spain. The institution of Dr. Arenillas has received research support from European Union - European Commission. The institution of Dr. Arenillas has received research support from Department of Education, Castilla y Leon Regional GVNT. Dr. Ayo Martin served as an Expert Witness for Daiichi-Sankyo. The institution of Dr. Ayo Martin has received research support from Daiichi-Sankyo. The institution of Dr. Ayo Martin has received research support from Spanish Society of Neurosonology. The institution of Dr. Montaner has received research support from Spanish govt. Dr. Montaner has received intellectual property interests from a discovery or technology relating to health care. The institution of Dr. Fischer has received research support from Medtronic. The institution of Dr. Fischer has received research support from Medtronic. The institution of Dr. Gralla has received research support from Medtronic. The institution of Dr. Michel served as a Consultant for Medtronic. Dr. Michel served on a Scientific Advisory or Data Safety Monitoring board for Penumbra. The institution of Dr. Michel has received research support from Swiss National Science Foundation; Swiss Heart Foundation. The institution of Dr. e Strambo has received research support from University of Lausanne. The institution of Dr. e Strambo has received research support from Swiss Heart Foundation. Dr. Catanese served as a Consultant for IschemiaCare. Dr. Demchuk served as a Consultant for Medtronic. Dr. Demchuk served on a Scientific Advisory or Data Safety Monitoring board for Lumosa. Dr. Demchuk served on a Speakers Bureau for Pfizer/BMS. Dr. Demchuk served on a Speakers Bureau for Boehringer Ingelheim. Dr. Demchuk has received stock or an ownership interest from Circle NVI. Dr. Demchuk has received intellectual property interests from a discovery or technology relating to health care. Dr. Field has received personal compensation for serving as an employee of Springer. Dr. Field served as an Expert Witness for Canadian Medical Protective Association. The institution of Dr. Field has received research support from Bayer Canada. Dr. Hill served as a Consultant for Boehringer Ingelheim. Dr. Hill served on a Scientific Advisory or Data Safety Monitoring board for Sun Pharma. Dr. Hill has received stock or an ownership interest from Circle Neurovascular. Dr. Saposnik served as a Consultant for Roche. Dr. Saposnik served as a Consultant for Celgene. Dr. Saposnik served as a Consultant for Servier. Dr. Saposnik served on a Scientific Advisory or Data Safety Monitoring board for NIHSS. The institution of Dr. Saposnik has received research support from Roche. The institution of Dr. Saposnik has received research support from Heart and Stroke Foundation of Canada. Dr. Shoamanesh served on a Scientific Advisory or Data Safety Monitoring board for Bayer AG. Dr. Shoamanesh served on a Scientific Advisory or Data Safety Monitoring board for

Daiichi Sankyo. Dr. Shoamanesh served on a Speakers Bureau for Servier Inc. Dr. Shoamanesh served as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurodiem.ca. The institution of Dr. Shoamanesh has received research support from Servier Canada Inc. The institution of Dr. Shoamanesh has received research support from Daiichi Sankyo Ltd. The institution of Dr. Shoamanesh has received research support from Bayer AG. The institution of Dr. Shoamanesh has received research support from Bristol-Myers Squibb. The institution of Dr. Shoamanesh has received research support from Octapharma Canada Dr. Abraham served as a Consultant for Stryker Neurovascular. An immediate family member of Dr. Altschul has received personal compensation in the range of \$50,000-\$99,999 for serving as a Consultant for Microvention and Stryker . The institution of Dr. Altschul has received research support from Max Kade. Dr. Badruddin has received intellectual property interests from a discovery or technology relating to health care. Dr. Chaturvedi served as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. Dr. Chaturvedi served as an Expert Witness for Various. The institution of Dr. Chaturvedi has received research support from NINDS. Dr. Choi has received intellectual property interests from a discovery or technology relating to health care. Dr. Devlin served as a Consultant for Neural Analytics. Dr. Devlin served as a Consultant for Viz.ai. Dr. Devlin served as a Consultant for Medtronic. Dr. Devlin served on a Speakers Bureau for Medtronic. Dr. Devlin served on a Speakers Bureau for Viz.ai. Dr. Devlin served as an officer or member of the Board of Directors for Neuroscience Innovation Foundation. Dr. Devlin has received stock or an ownership interest from Neural Analytics. Dr. Devlin has received stock or an ownership interest from Viz.ai. The institution of Dr. Devlin has received research support from Viz.ai. Dr. Devlin has received research support from Neural Analytics. Dr. Etherton served as a Consultant for WorldCare Clinical. Dr. Etherton has received research support from American Academy of Neurology. Dr. Etherton has received research support from MGH Executive Council on Research. Dr. Etherton has received publishing royalties from a publication relating to health care. Dr. Frei served as a Consultant for Philips. Dr. Frei served as a Consultant for Stryker. Dr. Frei served as a Consultant for Siemens. Dr. Frei served on a Scientific Advisory or Data Safety Monitoring board for Shape Memory Medical. Dr. Frei served on a Speakers Bureau for Genentech. Dr. Frei served on a Speakers Bureau for Stryker. Dr. Frei served on a Speakers Bureau for Penumbra. Dr. Frei served on a Speakers Bureau for Viz.AI. Dr. Frei has received stock or an ownership interest from Penumbra. Dr. Frei has received research support from Penumbra. Dr. Ameer Hassan served as a Consultant for Medtronic. Dr. Hassan served as a Consultant for Stryker. Dr. Hassan served as a Consultant for Penumbra. Dr. Hassan served as a Consultant for Cerenovus. Dr. Hassan served as a Consultant for Viz.ai. Dr. Hassan served on a Speakers Bureau for Genentech. Dr. Hassan has received research support from GE Healthcare. Dr. Leung has received research support from NIH. Dr. Linfante has received personal compensation for serving as an employee of Medtronic. Dr. Linfante has received personal compensation for serving as an employee of Stryker. Dr. Linfante has received personal compensation for serving as an employee of Cerenovus. Dr. Linfante has received personal compensation in the range of \$100,000-\$499,999 for serving as a Consultant for Medtronic. Dr. Linfante has received stock or an ownership interest from InNeuroCO. Dr. Linfante has received stock or an ownership interest from Stryker/Surpass. Dr. Lutsep served as a Consultant for Abbott. Dr. Lutsep served on a Scientific Advisory or Data Safety Monitoring board for BMS. Dr. Lutsep served on a Scientific Advisory or Data Safety Monitoring board for Coherex Medical. Dr. Lutsep served on a Scientific Advisory or Data Safety Monitoring board for NINDS/Mayo Clinic. Dr. Lutsep served as an Editor, Associate Editor, or Editorial Advisory

Board Member for Medscape Neurology. Dr. McDermott has served as an Editor, Associate Editor, or Editorial Advisory Board Member for American College of Cardiology. Dr. McDermott served as an Expert Reviewer with Michigan LARA. Dr. McDermott has a non-compensated relationship as a Consultant with Mitovation that is relevant to AAN interests or activities. Dr. Nahab served as an Expert Witness for Legal Consultation. Dr. Nahab has received intellectual property interests from a discovery or technology relating to health care. Dr. Ortega Gutierrez served as a Consultant for Stryker. Dr. Ortega Gutierrez served as a Consultant for Medtronic. Dr. Ortega Gutierrez served as an officer or member of the Board of Directors for SVIN. The institution of Dr. Ortega Gutierrez has received research support from Stryker. Dr. Ramakrishnan served as a Symposium Honorarium with Cerenovus. The institution of Dr. Romero has received research support from NIH/NIA. Dr. Rost served on a Scientific Advisory or Data Safety Monitoring board for Omiox. Dr. Rost served on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Rost served as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke - AHA/ASA Journal. The institution of Dr. Rost has received research support from NIH. Dr. Rost has received intellectual property interests from a publication relating to health care. Dr. Rost served as an Instructor with Heart and Rhythm Society. Dr. Ruland served as an Editor, Associate Editor, or Editorial Advisory Board Member for Up to Date. Dr. Ruland served as an Expert Witness for Law Firms. Dr. Silver served as an Expert Witness for Various legal firms. Dr. Silver has received intellectual property interests from a discovery or technology relating to health care. Dr. Silver has received publishing royalties from a publication relating to health care. Dr. Silver has received publishing royalties from a publication relating to health care. Dr. Silver has received publishing royalties from a publication relating to health care. Dr. Silver served as a Consultant with Women's Health Initiative. Dr. Silver served as a Consultant with Best Doctors, Inc.. Dr. Silver has a non-compensated relationship as a Consultant with ABPN that is relevant to AAN interests or activities. Dr. Silver has a non-compensated relationship as a Member, Regional Board of Directors with American Heart Association that is relevant to AAN interests or activities. Dr. Szeder served as a Consultant for Medtronic. Dr. Szeder served as an Expert Witness for Carroll, Kelly, Trotter, Franzen, McBride & Peabody LLP. Dr. Szeder served as an Expert Witness for Peabody and Buccini LLP. Dr. Tsai served as a Consultant for Cerenovus. Dr. Conforto has received research support from NIH. Dr. Conforto has received research support from FAPESP. Dr. Conforto has received research support from CNPq. Dr. Conforto has received research support from MIT. Dr. Conforto served as a Author with Springer. Dr. Conforto served as a speaker with Manole. Dr. Conforto served as a speaker with EEP-USP. Fabricio Oliveira Lima served on a Speakers Bureau for boehringer ingelheim. Dr. Lavados served on a Scientific Advisory or Data Safety Monitoring board for Boehringer Ingelheim. Dr. Lavados served on a Speakers Bureau for Boehringer Ingelheim. Dr. Lavados has received research support from ANID-FONDECYT. Dr. Hankey, MBBS,FR served as a Consultant for Bayer. Dr. Hankey, MBBS,FR served on a Scientific Advisory or Data Safety Monitoring board for AC Immune. Dr. Hankey, MBBS,FR served as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. Dr. Thijs served as a Consultant for Medtronic. Dr. Thijs served as a Consultant for Allergan. Dr. Thijs served as a Consultant for BMS. Dr. Thijs served on a Speakers Bureau for Pfizer. Dr. Thijs served on a Speakers Bureau for Boehringer Ingelheim. Dr. Haussen served as a Consultant for Stryker. Dr. Haussen has received stock or an ownership interest from Viz AI. Dr. Liebeskind has received research support from Cerenovus. Dr. Liebeskind has received research support from Genentech . Dr. Liebeskind has received research

support from Medtronic. Dr. Liebeskind has received research support from Stryker. Dr. Yavagal served as a Consultant for Johnson & Johnson. Dr. Yavagal served as a Consultant for Neural Analytics, Inc. Dr. Yavagal served as a Consultant for RAPID MEDICAL LTD.. Dr. Yavagal served as a Consultant for Guidepoint Global. Dr. Yavagal served on a Scientific Advisory or Data Safety Monitoring board for Neural Analytics, Inc. Dr. Yavagal served on a Scientific Advisory or Data Safety Monitoring board for Carnival Cruises. Dr. Yavagal served on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Yavagal served on a Scientific Advisory or Data Safety Monitoring board for Royal Caribbean Cruises Ltd.. Dr. Yavagal served on a Scientific Advisory or Data Safety Monitoring board for Guidepoint Global. Dr. Yavagal served on a Speakers Bureau for Medtronic. Dr. Yavagal served as an Editor, Associate Editor, or Editorial Advisory Board Member for Goldberg Segalla LLP. Dr. Yavagal served as an Expert Witness for Rourke and Blumenthal, LLP. Dr. Yavagal served as an Expert Witness for Eadie Hill Trial Lawyers. Dr. Yavagal served as an Expert Witness for Goldberg Segalla LLP. Dr. Jovin served as a Consultant for Cerenovus. Dr. Jovin served on a Scientific Advisory or Data Safety Monitoring board for Contego Medical. Dr. Jovin served as an Expert Witness for Several law firms. Dr. Jovin has received stock or an ownership interest from Corindus. Dr. Jovin has received stock or an ownership interest from Methinks. Dr. Jovin has received stock or an ownership interest from Viz.ai. The institution of Dr. Jovin has received research support from Stryker. The institution of Dr. Jovin has received research support from Medtronic. The institution of Dr. Nguyen received research support from Medtronic and SVIN.

The remaining authors report no disclosures relevant to the manuscript.

Abstract

Objective:

The objectives of this study were to measure the global impact of the pandemic on the volumes for intravenous thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March 1 to June 30, 2020) compared with two control 4-month periods.

Methods:

We conducted a cross-sectional, observational, retrospective study across 6 continents, 70 countries, and 457 stroke centers. Diagnoses were identified by their ICD-10 codes and/or classifications in stroke databases.

Results:

There were 91,373 stroke admissions in the 4 months immediately before compared to 80,894 admissions during the pandemic months, representing an 11.5% (95%CI, -11.7 to -11.3, $p < 0.0001$) decline. There were 13,334 IVT therapies in the 4 months preceding compared to 11,570 procedures during the pandemic, representing a 13.2% (95%CI, -13.8 to -12.7, $p < 0.0001$) drop. Interfacility IVT transfers decreased from 1,337 to 1,178, or an 11.9% decrease (95%CI, -13.7 to -10.3, $p = 0.001$). Recovery of stroke hospitalization volume (9.5%, 95%CI 9.2-9.8, $p < 0.0001$) was noted over the two later (May, June) versus the two earlier (March, April) pandemic months. There was a 1.48% stroke rate across 119,967 COVID-19 hospitalizations. SARS-CoV-2 infection was noted in 3.3% (1,722/52,026) of all stroke admissions.

Conclusions:

The COVID-19 pandemic was associated with a global decline in the volume of stroke hospitalizations, IVT, and interfacility IVT transfers. Primary stroke centers and centers with higher COVID19 inpatient volumes experienced steeper declines. Recovery of stroke hospitalization was noted in the later pandemic months.

ACCEPTED

Introduction

The coronavirus disease-2019 (COVID-19) pandemic has restructured healthcare systems worldwide to care for critically ill patients with COVID-19.¹ The high virulence of severe acute respiratory coronavirus 2 (SARS CoV-2) and the COVID-19 related disease morbidity and mortality have strained paradigms of health care worldwide. Several neurological manifestations have been reported in association with SARS-CoV-2 including ischemic, hemorrhagic, and cerebral venous stroke. Whereas infection can trigger an inflammatory prothrombotic cascade and ischemic stroke, stroke can induce immune dysregulation and expose a patient's vulnerability to infection.² The heterogeneity of stroke subtypes that have emerged in association with SARS-CoV-2^{3,4} suggests heterogeneous mechanisms of stroke including endothelial dysfunction, thrombotic diathesis, and non-specific effects of inflammation.⁵ Patients with COVID-19 associated stroke have been reported to have a higher risk for severe disability and mortality.^{4,6,7}

While there has been an increase in thromboembolic events reported with COVID-19,⁸ a decline in acute stroke code activations, stroke hospitalizations, and mechanical thrombectomy volumes have been reported at local, regional, and national levels,^{9,10,11,12,13} with most reports from comprehensive stroke centers (CSC) in highly resourced countries. There is a relative paucity of information on the effect of the pandemic on acute stroke hospitalization volume and intravenous thrombolysis (IVT) acute treatment in low or middle-income countries, and in primary stroke centers without

endovascular capability. There is also little information on the recovery of volumes in the later phases of the pandemic.

Objectives and Pre-specified Hypothesis

In this context, the present study aims to broaden the scope of evaluating the impact of the COVID-19 pandemic on global stroke care to include developed and developing nations in the early and later phases of the COVID-19 pandemic. Our primary aim was to evaluate the impact of COVID-19 on stroke care as measured by the changes in volumes for (1) overall stroke hospitalizations (2) IVT treatment (both direct presenting and patients transferred with IVT) for acute stroke across the pre-pandemic and pandemic periods in a multinational pool of PSCs and CSCs. In a secondary aim, the pandemic months were divided into an early (March 1, 2020, to April 30, 2020) and later phase (May 1, 2020, to June 30, 2020) to evaluate for stroke or IVT volume recovery in the later months.

We hypothesized that, in the face of the pandemic's strain on healthcare infrastructure, (1) a global reduction in all three aforementioned measurements of stroke care would occur over the pandemic in relation to both pre-pandemic periods, (2) hospitals with higher COVID-19 inpatient volumes would report greater decreases in stroke admissions, IVT volumes (direct and transfers) compared to hospitals with lower COVID-19 inpatient volumes, (3) the degree of decline in stroke hospitalizations and IVT volumes would be less profound in CSC compared to PSC (4) a geographic variation would exist in the intensity of decline in stroke care (5) a recovery in stroke

hospitalizations and IVT volumes would be observed in the two later pandemic months versus the early pandemic period.

METHODS

Study Design

This was a cross-sectional, observational, retrospective study evaluating monthly volumes of consecutive patients hospitalized with a diagnosis of COVID-19, stroke, IVT treatment, and IVT transfers. The diagnoses were identified by their related ICD-10 codes (primary, secondary, or tertiary discharge codes) and/or classifications in clinical stroke databases maintained at participating centers. Case ascertainment was verified by a physician or stroke coordinator.

Setting and Participants

Data were collected from collaborators of the Society of Vascular and Interventional Neurology (SVIN) including the Latin America Stroke Group, Middle East North Africa Stroke and Interventional Neurotherapies Organization (MENA-SINO), the Japanese Society of Vascular & Interventional Neurology Society (JSVIN), and academic partners from 6 continents, 70 countries, and 457 centers. Centers were screened for potential external confounders that could explain any unexpected changes in volumes. Of the 457 centers, 54 centers were excluded due to incomplete data or confounders. One center in Africa (Zimbabwe) was excluded due to a health care worker strike from September to January. One center in Egypt was excluded due to the ER being closed most days in June 2020. One center in Arkansas was excluded from the stroke

hospitalization volume analysis because this center became the designated center for all stroke patients in their region during the pandemic, resulting in an abrupt increase in their stroke volumes. One center in Malaysia was excluded as this was a new center in May 2020. Of the remaining 403 hospitals, 285 centers contributed to both stroke and thrombolysis volume data. For IVT transfers, centers with a mean of 4 or more transfers per month during the baseline control period were included.

We compared the stroke, IVT, IVT transfer diagnosis in the four initial months of the pandemic (March 1, 2020, to June 30, 2020) with (1) the immediately preceding four months (November 2019 to February 2020) as the primary analysis and (2) the equivalent four months in the previous year (March 1, 2019, to June 30, 2019) as the secondary analysis. The primary analysis provided a picture of stroke care utilization prior to COVID-19, whereas the secondary analysis allowed for the adjustment for seasonal variations in the risks for stroke.¹⁴

Study Variables and Outcomes Measures

Stroke hospitalization was defined as a patient admitted to a hospital with a transient ischemic attack (TIA), ischemic stroke, or intracerebral hemorrhage. IVT was defined as a patient with acute ischemic stroke receiving intravenous thrombolysis. IVT transfer was defined as a patient who was treated with IVT and transferred to another stroke center. Centers were asked not to duplicate IVT patients if both referral and recipient centers were included in this analysis; the IVT patient was computed with the referring center, and as an IVT transfer for the recipient hospital. COVID-19 hospitalization was

defined as any patient admitted with COVID-19 diagnosis to the hospital, which could encompass non-neurological diagnosis.

Median monthly volumes for overall stroke hospitalizations, IVT treatments for direct presenting and transfer patients were computed and compared across the pandemic and pre-pandemic periods for the overall population and across the low, intermediate, and high volume strata based on mean monthly volume tertiles for COVID-19 hospitalizations (≤ 6.2 vs. >6.2 to 61.9 vs. >61.9 COVID-19 admissions/month), stroke admissions (≤ 39.0 vs. >39.0 to 72.9 vs. >72.9 stroke admissions/month) and IVT volume (≤ 4.0 vs. >4.0 to 10.0 vs. >10.0 IVT/month).

Standard Protocol Approvals, Registration, and Patient Consents

This was an investigator-initiated project. The first and last authors wrote the first draft of the manuscript with subsequent input of all co-authors. There were no external funding sources. The institutional review boards from the coordinating sites (Emory University School of Medicine and Boston University School of Medicine) considered that the investigators did not have access to identifiable protected health information and thus no informed consent or IRB oversight was required since the study did not meet the federal description of human subject research.

Data Availability

The authors declare that all supporting data are available within the article.

Supplemental data are available from Dryad (Tables e-1 to e-6, Figure e-1, e-2,

<https://doi.org/10.5061/dryad.g1jwstqpw>). Anonymized data are available upon reasonable request.

STATISTICS

The monthly volumes for IVT and stroke hospitalizations were compared for the period before (1-year and immediately before) and during the COVID-19 pandemic. The normality of the data was tested with the Shapiro Wilk test. The nonparametric Wilcoxon signed-rank test was applied to compare differences in monthly volume between two time periods. The analyses were repeated in the setting of low, intermediate, and high COVID-19 and Stroke volume hospitals.

We looked at the percentage change in the number of IV thrombolysis and stroke admissions before and during the COVID-19 pandemic. The 95% confidence intervals for percentage change were calculated using the Wilson procedure without correction for continuity. The relative percentage decrease in volume between low, intermediate, and high-volume hospitals was tested using the z-test of proportion. All data were analyzed using SAS version 9.4 (SAS Institute), and the significance level was set at a P-value of $<.05$.

RESULTS

There were 82,465, 91,373 and 80,894 stroke hospitalizations (overall $n=254,732$) and 12,527, 13,334 and 11,570 IVT therapies (overall $n=37,431$) included across the 4-month prior-year pandemic, 4-month immediately pre-pandemic and 4-month pandemic

periods, respectively. Country-specific data contributions and relative changes across the pandemic are summarized in Dryad Table e-3.

Stroke Hospitalization

Monthly stroke hospitalization as compared with COVID-19 hospitalization volumes are represented in Figure 1. In the primary analysis, there were 91,373 hospitalizations in the 4 months of the pre-pandemic period compared to 80,894 during the pandemic months, representing an 11.5% drop (95%CI, -11.7 to -11.3 $p < 0.0001$; monthly median [IQR] stroke hospitalization volume/center 54.0 [30.8-86.5] to 43.0 [24.3-71.3], $p < 0.0001$, N=325 sites) (Table 1). There was geographic variation of the decline in stroke hospitalization: Asia, -7.1% (95%CI, -7.4 to -6.9, $p < 0.0001$); North America, -18.8% (95%CI, -19.3 to -18.3, $p < 0.0001$); Europe, -10.0% (95%CI, -10.4 to -9.6, $p < 0.0001$); South America, -17.4% (95%CI, -18.5 to -16.3, $p < 0.0001$); Africa, -30.2% (95%CI, -32.2 to -28.3, $p < 0.0001$); whereas Oceania (-1.9%;95%CI, -2.5 to -1.5, $p = 0.3$) did not demonstrate significance (Dryad Table e-1). Primary stroke centers -17.3% (95%CI, -17.9 to -16.7, N=89) demonstrated greater declines compared to comprehensive stroke centers -10.3%(95%CI, -10.6 to -10.1, N=236) (Table 1).

Intravenous Thrombolysis

Intravenous thrombolytic volumes declined with 13,334 interventions in the pre-pandemic period versus 11,570 during the pandemic, representing a 13.2% drop (95%CI, -13.8 to -12.7, $p < 0.001$; median [IQR] monthly IVT volume/center 6.2 [2.8-12.0] to 5.3[2.0-10.5], $p < 0.001$, N=389 centers) (Table 2, Figure 2). IVT decline was seen in

most continents: Asia, -10.1% (95%CI, -11.2 to -9.1, $p<0.0001$); North America, -14.4% (95%CI, -15.6 to -13.3, $p<0.0001$); Europe, -13.4% (95%CI, -14.3 to -12.5, $p<0.0001$); South America, -24.2% (95%CI, -27.6 to -21.0, $p<0.0001$); Africa -23.5% (95%CI, -29.8 to -18.2, $p<0.01$). There was no appreciable difference in IVT in Oceania -1.9% (95%CI, -3.9 to -0.92, $p=0.7$) (Dryad Table e-2). IVT declines were greater in PSCs -15.5% (95%CI, -16.9 to -14.2, $N=138$ centers) versus CSCs -12.6% (95%CI, -13.3 to -12.0, $N=251$ centers, $p=0.0001$) (Table 2).

Recovery of Stroke and IVT Volume Analysis

In the recovery analysis, there were 38,616 stroke hospitalizations in the early 2 months of the pandemic compared to 42,278 stroke hospitalizations in the later 2 pandemic months, representing an increase of 9.5% (95%CI, 9.2-9.8, $p<0.0001$, $N=325$ centers). The recovery in stroke hospitalization volume was seen in all strata of COVID-19 hospitalization burden, with a gradient of recovery more significant in low (14.6%; 95%CI 14.0-15.2, $p<0.0001$) vs. intermediate (9.0%; 95%CI 8.4-9.5, $p<0.0001$) vs. high-volume (4.6%; 95% CI 4.2-5.0, $p<0.0001$) COVID-19 hospitalization. There was a gradient in stroke hospitalization recovery by baseline hospital stroke volume, significant in high-volume (13.9%; 95% CI 13.5-14.3, $p<0.0001$) stroke centers compared to intermediate or low volume centers, which in their strata, did not demonstrate significance in recovery. Stroke hospitalization volume recovery was more significant in comprehensive (10.9%; 95%CI 10.6-11.3, $p<0.0001$) compared to primary stroke centers (1.8%; 95%CI 1.5-2.1, $p=0.3$) (Table 3).

Intravenous thrombolysis was administered to 5,714 patients in the early pandemic compared to 5,856 patients in the later pandemic months, representing a non-significant increase of 2.5% (95%CI 2.1-2.9, $p=0.19$). Recovery in IVT volume was more significant in intermediate (6.1%, 95%CI 5.0-7.4) vs. low (2.6%, 95%CI 1.9-3.6, $p<0.0001$) COVID-19 hospitalization centers. A trend in IVT volume recovery was seen with CSCs (4.1%, 95% CI 3.6-4.7, $p=0.053$).

IVT Transfer Analysis

There were 1,337 IVT transfers in the pre-pandemic compared to 1,178 in the pandemic months, representing an 11.9% drop (95%CI, -13.7 to -10.3, $p=0.001$). The IVT transfer declines were significant in the strata of hospitals with low (-18.3%, 95%CI -23.9 to -13.9, $p=0.03$) and high (-14.9%, 95%CI -18.1 to -12.1, $p=0.008$) COVID-19 volume (Table 4).

Secondary analysis

Table 5 reveals the volumes for stroke hospitalizations, IVT, and IVT transfers during the first four months of the pandemic versus the corresponding period in the prior year.

There were significant declines in the overall and monthly volumes for all metrics.

Intersection of COVID-19, SARS CoV-2 infection, and Stroke Hospitalizations

A total of 269 centers provided data on SARS CoV-2 infection and diagnosis of stroke in the same patient. A diagnosis of any stroke was present in 1.48% (1778/119,967) of COVID-19 hospitalizations, with continental variation: Africa 1.6% (47/2879), Asia 1.5%

(317/20858), Oceania 0.4% (1/257), Europe 1.4% (507/36,871), North America 1.2% (615/49,237), South America 3.0% (291/9865) (Dryad Table e-5).

SARS-CoV-2 infection was present in 3.3% (1722/52,026) of stroke hospitalizations (Dryad Table e-5) with continental variation: Africa 3.1% (56/1828), Asia 2.7% (342/12,686), Oceania 0.5% (1/186), Europe 3.3% (502/15,220), North America 3.0% (527/17,855), South America 8.4% (294/3505) (Dryad Table e-6).

DISCUSSION

In this temporal analysis of more than 254,000 stroke hospitalizations worldwide, there was a global decrease in stroke admissions (-11.5%), intravenous thrombolysis (-13.2%), and IVT transfers (-11.9%) during the first four pandemic months, compared to the immediately preceding period, confirming our primary hypothesis. A decrease in volume was also seen in relation to the equivalent period in the prior year for all metrics. The declines in both stroke hospitalization and IVT were greater in PSCs compared to CSCs. Recovery of stroke hospitalization volume (+9.5%) was noted in the two subsequent months versus the two initial months of the pandemic, with greater recovery in hospitals with lower COVID-19 hospitalization volume, high volume stroke center, and comprehensive stroke centers.

The decreases in the volume of stroke care provided were noted across centers with high, intermediate, and low COVID-19 hospitalization burden, and also across high, intermediate, and low volume stroke and IVT centers. As hypothesized, the magnitude

of decrease of stroke hospitalizations and IVT was greater in centers with higher COVID-19 inpatient volumes.

Our results concur with other recent reports on the collateral effects of the COVID-19 pandemic on stroke systems of care including studies from China,¹¹ Italy,¹⁵ Spain,¹⁰ France,^{12,16} Germany,¹⁷ Brazil,¹⁸ Canada¹⁹ and the United States.^{9,20,21,22} Although prior analyses have described temporal and regional changes in stroke hospitalizations and IVT, this is among the first descriptions of the change at a global level, including primary and comprehensive stroke centers. Hospital access related to high COVID-19 burden was unlikely a factor, as the decline was seen in centers with low or non-existent COVID-19 patients.^{23,24} The patient's fear of contracting coronavirus may have played a role along with a decrease in presentation of TIA, mild, or moderate strokes as reported by Diegoli et al.¹⁸ Physical distancing measures may have prevented patients from the timely witnessing of a stroke. Similar to cardiovascular events, it is conceivable that there was a true population-level reduction in cerebrovascular events, possibly related to decreased consumption of high-sodium, fast-foods, reduced exposure to ambient air pollution, or improvement in patient behaviors.²⁴ A reduction in exposure to other common viruses that may play a role in triggering vascular events may have also reduced stroke risk.

In the recovery analysis, there was a gradient of recovery in stroke hospitalization in hospitals with lower compared to higher COVID-19 burden. Further, comprehensive stroke centers and high-volume stroke centers demonstrated greater recovery,

suggesting patients with a higher acuity of care needs seeking care in these comprehensive centers.

Our subgroup of 264 centers including 119,967 COVID-19 hospitalizations expands on prior MT analysis that was limited to CSCs (Nogueira) and represents the largest sample reporting the concomitant diagnoses of stroke and SARS-CoV-2 infection to date. Our 1.48% stroke rate in COVID-19 hospitalizations is similar to the pooled incidence of 1.1 to 1.2% (range, 0.9%-2.7%) of hospitalized COVID-19 patients.⁴ The higher rate may be explained in part by the higher number of patients contracting SARS-CoV-2 over time and higher availability of testing. Some variation in the proportions are expected given the different definitions (all strokes vs. ischemic only) and populations involved (all hospitalized vs. severely infected only) across studies. We also provide another perspective on this relationship by reporting an incidence of 3.3% (1722/52,026) for SARS-CoV-2 infection across all stroke hospitalizations among centers with documented COVID-19 hospitalization.

Finally, twenty-five years after the landmark NINDS trials showing the benefit of tPA, we learned from this global analysis that as of the year 2020, the availability of IVT for acute stroke therapy continues to be lacking in multiple countries in Africa (i.e. Nigeria, Kenya, Zimbabwe, Ghana, Ethiopia, Sudan) owing to its high cost and relative implementation complexity, limiting our analysis of temporal IVT treatment trends for this continent. More importantly, this void highlights a disparity of access to basic stroke therapy in multiple low-income countries across the world.

Study strengths and limitations

To our knowledge, this is the largest global study to date evaluating the intersection of the COVID-19 pandemic with stroke care. Our study included the participation of diverse geography of centers from 6 continents, 70 countries, 457 comprehensive and primary stroke centers.

Our study has several limitations. The diagnosis of stroke/TIA in some centers was obtained using administrative coding of hospital ICD codes and hence there is a possibility of misclassification of diagnosis, potentially compounded by regional and national variations in stroke diagnosis and delivery of care. However, centers contributing to these data have systems to track stroke metrics of care, thus, the relative changes in volume from this analysis are likely robust. Details on patient-level data including demographics, stroke subtypes, and clinical outcomes were not collected as these were outside the scope of the study. The definition of the pandemic period was arbitrary since the outbreak started and peaked at different times at different locations. This led to the computation of relative increases in volumes during the study period in the earlier affected regions, such as China, resulting in a potential underestimation of the global impact. Finally, the sampling varied with the availability of complete data in each subset of the analysis.

Conclusion

The COVID-19 pandemic was associated with an initial global decline in the volume of stroke hospitalizations, IVT, and interfacility IVT transfers. These reductions were

observed regardless of COVID-19 hospitalization burden, pre-pandemic stroke, and IVT volumes. Primary stroke centers and centers with higher COVID19 inpatient volumes experienced steeper declines. Recovery of stroke hospitalization but not IVT volume was noted in the later phase of the pandemic months and associated with lower COVID-19 hospital burden, high volume, and comprehensive stroke centers. The findings of our study can inform future studies, preparedness,²⁵ and local policies in the event of a second COVID-19 surge or future pandemic.

Appendix 2. Coinvestigators

Name, Degree	Location	Role	Contribution
Judith Clark, RN	Boston Medical Center, USA	Collaborator	Contribution of data
Cheryl Grant, RN	Neurology, Medical University of South Carolina, Charleston, USA	Collaborator	Contribution of data
Mazlina Husin, MMed	Hospital Sultanah Nur Zahirah Kuala Terengganu, Malaysia	Collaborator	Contribution of data
Crivorucica Igor, MD	Emergency Medicine Institute, Chisinau, Republic of Moldova	Collaborator	Contribution of data
Steve Withington, MD, FRACP	Ashburton Hospital, Ashburton, New Zealand	Collaborator	Contribution of data
Mandy Lau, MD	University of Melbourne, Ballarat Health Service, Australia	Collaborator	Contribution of data
Thomas Kraemer, MD	University of Melbourne, Ballarat Health Service, Australia	Collaborator	Contribution of data

REFERENCES

1. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. *New England Journal of Medicine*. 2020;382:2049-2055.
2. Elkind MSV, Boehme AK, Smith CJ, Meisel A, Buckwalter MS. Infection as a Stroke Risk Factor and Determinant of Outcome After Stroke. *Stroke*. 2020;51:3156-3168.
3. Yaghi S, Ishida K, Torres J, Mac Grory B, Raz E, Humbert K, et al. SARS-CoV-2 and Stroke in a New York Healthcare System. *Stroke*. 2020;51(7):2002-2011.
4. Siegler JE, Cardona P, Arenillas JF, Talavera B, Guillen AN, Chavarria-Miranda A, et al. Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry. *Int J Stroke*. Published online August 27, 2020:1747493020959216.
5. Hernández-Fernández F, Valencia HS, Barbella-Aponte RA, Collado-Jimenez R, Ayo-Martin O, Barrena C, et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. *Brain*. 2020;143(10):3089-3103.
6. Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, Xion J, et al. Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry. *Stroke*. 2020;51(9):e254-e258.
7. Tsvigoulis G, Katsanos AH, Ornello R, Sacco S. Ischemic Stroke Epidemiology During the COVID-19 Pandemic: Navigating Uncharted Waters With Changing Tides. *Stroke*. 2020;51(7):1924-1926.
8. Ma A, Kase CS, Shoamanesh A, Abdalkader M, Pikula A, Sathya A, et al. Stroke and Thromboprophylaxis in the era of COVID-19. *Journal of Stroke and Cerebrovascular Diseases*. 2020;30(1):105392.
9. Huang JF, Greenway MRF, Nasr DM, Chukwudelunzu FE, Demaerschalk BM, O'Carroll CB, et al. Telestroke in the Time of COVID-19: The Mayo Clinic Experience. *Mayo Clin Proc*. 2020;95(8):1704-1708.
10. Rudilosso S, Laredo C, Vera V, Vargas M, Renu A, Llull L, et al. Acute Stroke Care Is at Risk in the Era of COVID-19: Experience at a Comprehensive Stroke Center in Barcelona. *Stroke*. 2020;51(7):1991-1995.
11. Zhao J, Li H, Kung D, Fisher M, Shen Y, Liu R. Impact of the COVID-19 Epidemic on Stroke Care and Potential Solutions. *Stroke*. 2020;51(7):1996-2001.
12. Kerleroux B, Fabacher T, Bricout N, Moise M, Testud B, Vingadassalom S, et al. Mechanical Thrombectomy for Acute Ischemic Stroke Amid the COVID-19 Outbreak: Decreased Activity, and Increased Care Delays. *Stroke*. 2020;51(7):2012-2017.
13. Kristoffersen ES, Jahr SH, Thommessen B, Rønning OM. Effect of COVID-19 pandemic on stroke admission rates in a Norwegian population. *Acta Neurol Scand*. 2020;142(6):632-636.

14. Han M-H, Yi H-J, Kim Y-S, Kim Y-S. Effect of seasonal and monthly variation in weather and air pollution factors on stroke incidence in Seoul, Korea. *Stroke*. 2015;46(4):927-935.
15. Sacco S, Ricci S, Ornello R, Eusebi P, Petraglia L, Toni D, et al. Reduced Admissions for Cerebrovascular Events During COVID-19 Outbreak in Italy. *Stroke*. 2020;51(12):3746-3750.
16. Pop R, Quenardelle V, Hasiu A, Mihoc D, Sellal F, Dugay MH, et al. Impact of the COVID-19 outbreak on acute stroke pathways - insights from the Alsace region in France. *Eur J Neurol*. 2020;27(9):1783-1787.
17. Hoyer C, Ebert A, Huttner HB, Puetz V, Kallmunzer B, Barlinn K, et al. Acute Stroke in Times of the COVID-19 Pandemic: A Multicenter Study. *Stroke*. 2020;51(7):2224-2227.
18. Diegoli H, Magalhães PSC, Martins SCO, Moro CHC, Franca PHC, Safanelli J, et al. Decrease in Hospital Admissions for Transient Ischemic Attack, Mild, and Moderate Stroke During the COVID-19 Era. *Stroke*. 2020;51(8):2315-2321.
19. Katsanos AH, de Sa Boasquevisque D, Al-Qarni MA, Shawawrah M, McNicoll-Whiteman R, Gould L, et al. In-Hospital Delays for Acute Stroke Treatment Delivery During the COVID-19 Pandemic. *Can J Neurol Sci*. 2020;1-7.
20. Siegler JE, Heslin ME, Thau L, Smith A, Jovin TG. Falling stroke rates during COVID-19 pandemic at a comprehensive stroke center. *J Stroke Cerebrovasc Dis*. 2020;29(8):104953.
21. Hsiao J, Sayles E, Antzoulatos E, Stanton RJ, Sucharew H, Broderick JP, et al. Effect of COVID-19 on Emergent Stroke Care: A Regional Experience. *Stroke*. 2020;51(9):e2111-e2114.
22. Uchino K, Kolikonda MK, Brown D, Kovi S, Collins D, Khawaja Z, et al. Decline in Stroke Presentations During COVID-19 Surge. *Stroke*. 2020;51(8):2544-2547.
23. Nogueira RG, Abdalkader M, Qureshi M, Frankel M, Mansour OY, Yamagami H. et al. Global Impact of the COVID-19 Pandemic on Stroke Hospitalizations and Mechanical Thrombectomy Volumes. *Int J Stroke*. 2021 Online ahead of print.
24. Nguyen TN, Haussen DC, Qureshi M, Yamagami H, Fujinaka T, Mansour OY, et al. Decline in subarachnoid hemorrhage volumes associated with the first wave of the COVID-19 pandemic. *Stroke and Vascular Neurology, in press*.
25. American Heart Association's Mission: Lifeline and Get With The Guidelines Coronary Artery Disease Advisory Work Group and the Council on Clinical Cardiology's Committees on Acute Cardiac Care and General Cardiology and Interventional Cardiovascular Care*. Temporary Emergency Guidance to STEMI Systems of Care During the COVID-19 Pandemic: AHA's Mission: Lifeline. *Circulation*. 2020;142(3):199-202.
26. Nguyen TN, Abdalkader M, Jovin TG, Nogueira RG, Jadhav AP, Haussen DC, et al. Mechanical Thrombectomy in the Era of the COVID-19 Pandemic: Emergency Preparedness for Neuroscience Teams: A Guidance Statement From the Society of Vascular and Interventional Neurology. *Stroke*. 2020;51(6):1896-1901.

27. Nguyen TN, Jadhav AP, Dasenbrock HH, Nogueira RG, Abdalkader M, Ma A, et al. Subarachnoid hemorrhage guidance in the era of the COVID-19 pandemic – An opinion to mitigate exposure and conserve personal protective equipment. *Journal of Stroke and Cerebrovascular Diseases*. 2020;29(9):105010.

ACCEPTED

Table 1. Stroke volumes immediately before and during the COVID-19 pandemic.

	Overall volume					Monthly volume				
	N	n1	n2	Relative (%) change	P	N	Immediately Before	During COVID-19	Difference* (95% CI)	P
				% (95% CI)			Median (IQR)			
Overall	325	91,373	80,894	-11.5(-11.7 - -11.3)	<0.0001	325	54.0(30.8-86.5)	43.0(24.3-71.3)	-6.7(-8.3 - -5.8)	<0.0001
Hospital COVID-19 volume[†]										
Low	85	29,835	28,890	-3.2(-3.4 - -3.0)	<0.0001	85	51.5(24.5-89.8)	46.3(21.5-86.3)	-3.0(-5.0 - 1.5)	0.002
Int.	102	24,849	21,879	-12.0(-12.4 - -11.6)	<0.0001	102	50.2(27.8-83.0)	38.8(24.5-68.0)	-7.5(-9.0 - -4.0)	<0.0001
High	91	26,575	21,913	-17.5(-18.0 - -17.1)	<0.0001	91	61.3(48.5-96.3)	49.0(35.8-71.3)	-11.3(-13.8 - -8.0)	<0.0001
Hospital Stroke volume[‡]										
Low	113	10,518	8,951	-14.9(-15.6 - -14.2)	<0.0001	113	23.5(16.5-31.0)	20.3(12.0-25.8)	-3.2(-4.3 - -2.0)	<0.0001
Int.	108	23,698	19,449	-17.9(-18.4 - -17.5)	<0.0001	108	55.1(48.0-61.3)	43.3(37.6-52.4)	-9.6(-11.0 - -7.7)	<0.0001
High	104	57,157	52,494	-8.2(-8.4 - -7.9)	<0.0001	104	105.2(87.9-146.3)	94.7(72.4-145.3)	-11.8(-16.0 - -8.5)	<0.0001
Primary vs Comprehensive Stroke Center[§]										
Primary	89	14,782	12,222	-17.3(-17.9 - -16.7)	<0.0001	89	31.5(19.8-52.0)	26.0(13.3-42.0)	-5.3(-8.0 - 4.0)	<0.0001
Comp.	236	76,591	68,672	-10.3(-10.6 - -10.1)	<0.0001	236	61.3(39.1-95.9)	51.4(30.4-85.7)	-7.5(-9.2 - -6.0)	<0.0001

Abbreviations: N= number of hospitals; n= number of admissions; Int=intermediate; Comp=Comprehensive; CI= confidence interval; IQR= inter-quartile range

Note: The n1 and “immediately before” are based on 4 months before the pandemic (November 2019 to February 2020).

The n2 and “During COVID-19” are based on March 2020 to June 2020.

P-value is from Poisson means test (overall volume analysis) and Wilcoxon signed-rank test (monthly volume analysis)

*Difference denotes the median difference between the two time periods

[†]P: Low vs Intermediate= <0.0001; Low vs High= <0.0001; Intermediate vs High= <0.0001

[‡]P: Low vs Intermediate= <0.0001; Low vs High= <0.0001; Intermediate vs High= <0.0001

[§]P: Primary vs Comprehensive= <0.0001

Table 2. Intravenous tPA procedure volumes immediately before and during the COVID-19 pandemic.

Overall volume						Monthly volume				
	N	n1	n2	Relative (%) change	P	N	Immediately Before	During COVID-19	Difference* (95% CI)	P
				% (95% CI)			Median (IQR)			
Overall	389	13,334	11,570	-13.2(-13.8 - -12.7)	<0.0001	389	6.5(2.8-12.0)	5.3(2.0-10.5)	-0.75(-1.0 - -0.50)	<0.0001
Hospital COVID-19 volume[†]										
Low	112	3,162	2,871	-9.2(-10.3 - -8.2)	<0.0001	112	3.5(1.5-8.5)	3.1(1.3-8.1)	-0.25(-0.50 - -0.19)	<0.0001
Int.	102	3,373	2,947	-12.6(-13.8 - -11.6)	<0.0001	102	6.3(3.3-13.0)	5.3(2.5-10.8)	-0.75(-1.0 - -0.25)	<0.0001
High	96	4,252	3,439	-19.1(-20.3 - -18.0)	<0.0001	96	9.1(5.6-15.3)	7.5(4.0-12.5)	-1.9(-2.5 - -1.0)	<0.0001
Hospital Intravenous tPA volume[‡]										
Low	133	1,052	929	-11.7(-13.8 - -9.9)	0.003	133	1.8(1.5-2.8)	1.3(1.0-2.5)	-0.19(-0.25 - -0.19)	0.007
Int.	133	3,553	3,049	-14.2(-15.4 - -13.1)	<0.0001	133	6.8(5.0-8.0)	5.3(3.8-7.3)	-1.0(-1.5 - -0.75)	<0.0001
High	123	8,729	7,592	-13.0(-13.8 - -12.3)	<0.0001	123	15.3(12.3-19.5)	13.8(10.3-17.8)	-2.3(-3.0 - -1.5)	<0.0001
Primary vs Comprehensive Stroke Center[§]										
Primary	138	2,763	2,334	-15.5(-16.9 - -14.2)	<0.0001	138	3.1(1.5-6.5)	2.1(1.3-5.5)	-0.25(-0.75 - 0.19)	<0.0001
Comp.	251	10,571	9,236	-12.6(-13.3 - -12.0)	<0.0001	251	8.8(4.5-14.0)	7.3(3.5-12.8)	-1.0(-1.3 - -0.50)	<0.0001

Abbreviations: tPA= tissue plasminogen activator; N= number of hospitals; n= number of procedures; Int= intermediate; Comp= comprehensive; CI= confidence interval; IQR= inter-quartile range

Note: The n1 and “immediately before” are based on 4 months before the pandemic (November 2019 to February 2020). The n2 and “During COVID-19” are based on March 2020 to June 2020.

P-value is from Poisson means test (overall volume analysis) and Wilcoxon signed-rank test (monthly volume analysis)

*Difference denotes the median difference between the two time periods

[†]P: Low vs Intermediate= <0.0001; Low vs High= <0.0001; Intermediate vs High= <0.0001

[‡]P: Low vs Intermediate= 0.038; Low vs High= 0.234; Intermediate vs High= 0.076

[§]P: Primary vs Comprehensive= 0.0001

Table 3. Stroke and Intravenous tPA overall volumes during early and late COVID-19 pandemic.

	Stroke*					Intravenous tPA†				
	N	Early COVID-19	Late COVID-19	Relative (%) change	P	N	Early COVID-19	Late COVID-19	Relative (%) change	P
				% (95% CI)					% (95% CI)	
Overall	325	38,616	42,278	9.5(9.2-9.8)	<0.0001	389	5,714	5,856	2.5 (2.1 - -2.9)	0.187
Hospital COVID-19 volume										
Low	85	13,461	15,429	14.6(14.0-15.2)	<0.0001	112	1,417	1,454	2.6 (1.9 - 3.6)	0.490
Int.	102	10,471	11,408	9.0(8.4-9.5)	<0.0001	102	1,430	1,517	6.1 (5.0 - 7.4)	0.109
High	91	10,712	11,201	4.6(4.2-5.0)	0.001	96	1,717	1,722	0.29 (0.12 - 0.68)	0.932
Hospital Stroke/Intravenous tPA volume										
Low	113	4,468	4,483	0.34(0.21-0.56)	0.874	133	464	465	0.22 (0.04 - 0.12)	0.974
Int.	108	9,604	9,845	2.5(2.2-2.8)	0.084	133	1,525	1,524	0.07 (0.01 - 0.38)	0.986
High	104	24,544	27,950	13.9(13.5-14.3)	<0.0001	123	3,725	3,867	3.8 (3.2 - 4.5)	0.103
Primary vs Comprehensive Stroke Center										
Primary	89	6,057	6,165	1.8(1.5-2.1)	0.329	138	1,189	1,145	-3.7 (-2.8 - -4.9)	0.363
Comp.	236	32,559	36,113	10.9(10.6-11.3)	<0.0001	251	4,525	4,711	4.1 (3.6 - 4.7)	0.053

Abbreviations: tPA= tissue plasminogen activator; N= number of hospitals; Int= intermediate; Comp= comprehensive; CI= confidence interval.

Note: The early and late COVID-19 periods are based on March 2020 to April 2020 and May 2020 to June 2020, respectively.

P-value is from Poisson means test

*Stroke volume analysis

Hospital COVID-19 volume: Low vs Intermediate= <0.0001; Low vs High= <0.0001; Intermediate vs High= <0.0001

Hospital Stroke volume: Low vs Intermediate= <0.0001; Low vs High= <0.0001; Intermediate vs High= <0.0001

Primary vs Comprehensive= <0.0001

†Intravenous tPA volume analysis

Hospital COVID-19 volume: Low vs Intermediate= <0.0001; Low vs High= <0.0001; Intermediate vs High= <0.0001

Intravenous tPA volume: Low vs Intermediate= 0.383; Low vs High= 0.0001; Intermediate vs High= <0.0001

Primary vs Comprehensive= n/a

Table 4. Intravenous tPA transfer volumes immediately before and during the COVID-19 pandemic.

Overall volume						Monthly volume				
	N	n1	n2	Relative (%) change	<i>P</i>	N	Immediately Before	During COVID-19	Difference* (95% CI)	<i>P</i>
				% (95% CI)			Median (IQR)			
Overall	39	1,337	1,178	-11.9 (-13.7 - -10.3)	0.001	39	7.5 (5.8-11.3)	7.3 (5.0-9.5)	-0.75 (-1.3 - 0.0)	0.027
Hospital COVID-19 volume[†]										
Low	7	229	187	-18.3 (-23.9 - -13.9)	0.032	7	6.5 (5.8-8.5)	6.8 (6.5-7.5)	-1.0 (-9.8 - 1.8)	0.688
Int.	14	428	404	-5.6 (-8.2 - -3.8)	0.341	14	7.5 (4.5-11.5)	7.5 (4.3-9.8)	-0.38 (-1.8 - 1.3)	0.352
High	14	538	458	-14.9 (-18.1 - -12.1)	0.008	14	8.0 (6.0-11.3)	6.8 (5.3-9.5)	-1.3 (-2.5 - 1.3)	0.107

Abbreviations: tPA= tissue plasminogen activator; N= number of hospitals; n= number of transfers; Int= intermediate; CI= confidence interval; IQR= inter-quartile range

Note: The n1 and “immediately before” are based on 4 months before the pandemic (November 2019 to February 2020). The n2 and “During COVID-19” are based on March 2020 to June 2020.

P-value is from Poisson means test (overall volume analysis) and Wilcoxon signed-rank test (monthly volume analysis)

*Difference denotes the median difference between the two time periods

[†]*P*: Low vs Intermediate= <0.0001; Low vs High= 0.239; Intermediate vs High= <0.0001

Table 5. Overall and monthly volumes 1 year before and during COVID-19 pandemic.

	Overall volume					Monthly volume				
	N	n1	n2	Relative (%) change	P	N	1-year before	During COVID-19	Difference* (95% CI)	P
				% (95% CI)			Median (IQR)			
Stroke	297	82,465	72,554	-12.0(-12.2 - -11.8)	<0.0001	297	50.3(28.3-80.8)	42.0(24.3-70.3)	-5.8(-7.8 - -4.5)	<0.0001
IV tPA	377	12,527	11,198	-10.6(-11.2 - -10.1)	<0.0001	377	6.0(2.3-12.0)	5.3(2.0-10.5)	-0.50(-0.75 - -0.25)	<0.0001
IV tPA transfer	36	1,331	1,140	-14.4(-16.3 - -12.6)	<0.0001	36	7.6(5.3-12.0)	7.5(5.5-9.5)	-1.1(-2.0 - 0.25)	0.038

Abbreviations: N= number of hospitals; n= number of admissions/procedures/transfers; CI= confidence interval; IQR= inter-quartile range; tPA= tissue plasminogen activator

Note: The n1 and “1-year before” are based on 4-month data 1 year before the pandemic (March 2019 to June 2019). The n2 and “During COVID-19” are based on data from March 2020 to June 2020.

P-value is from Poisson means test (overall volume analysis) and Wilcoxon signed-rank test (monthly volume analysis)

*Difference denotes the median difference between the two time periods

Figure 1. Monthly Stroke vs. Covid-19 Admissions




Figure 2. Monthly IV thrombolysis vs. COVID-19 admissions

